Bispecific antibody that recognizes CCR8 as antigen

A bispecific antibody targeting CCR8 and effector cell surface markers shows promise in treating cancers by inducing cytotoxic activity against CCR8-expressing cells, addressing the limitations of previous CCR8-targeting therapies.

WO2024248037A1PCT designated stage expired Publication Date: 2024-12-05SHIONOGI & CO LTD +1
View PDF 51 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019695
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current bispecific antibodies targeting CCR8 for cancer treatment have not demonstrated significant therapeutic effects, particularly in cancers where CCR8 is expressed in tumor cells, and there is a lack of evidence for their efficacy in targeting intratumoral infiltrating Treg cells.

Method used

Development of a bispecific antibody that recognizes CCR8 as an antigen, combining the anti-CCR8-scFv region with variable regions of antibodies targeting effector cells such as CD3 or CD16, to induce cytotoxic activity against CCR8-expressing tumor cells and Treg cells.

Benefits of technology

The bispecific antibody exhibits concentration-dependent cytotoxic activity against human CCR8-expressing cells, including tumor-infiltrating Treg cells, demonstrating potential as a therapeutic agent for various cancers by enhancing antitumor responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

Disclosed is a bispecific antibody that recognizes CCR8 as an antigen. It was found that the bispecific antibody has cytotoxic activity against CCR8-expressing cells.
Need to check novelty before this filing date? Find Prior Art

Description

Bispecific antibody that recognizes CCR8 as an antigen

[0001] The present invention relates to a bispecific antibody that recognizes CCR8 as an antigen, and a pharmaceutical composition containing the bispecific antibody.

[0002] CCR8, also known as CY6, CKR-L1, or TER1, is a G protein-coupled, seven-transmembrane CC chemokine receptor protein expressed in the thymus, spleen, etc., and its gene is located on 3p21 in human chromosome 3. Human CCR8 consists of 355 amino acids (Non-Patent Document 1). CCL1 is known as an endogenous ligand for CCR8 (Non-Patent Document 2). Human CCR8 cDNA consists of the nucleotide sequence shown in Genbank ACC No. NM_005201.3, and mouse CCR8 cDNA consists of the nucleotide sequence shown in Genbank ACC No. NM_007720.2.

[0003] CCR8 is specifically expressed in tumor-infiltrating Treg cells, and it has been shown that when breast cancer cells were transplanted into CCR8-deficient mice and wild-type mice, the growth and metastasis of breast cancer in the CCR8-deficient mice were suppressed compared to the wild-type mice (Patent Document 1 and Non-Patent Document 3). Non-Patent Documents 4 to 8 also describe the involvement of CCR8 in the pathology of cancer. Furthermore, it has been disclosed that administration of anti-CCR8 antibodies to cancer model animals showed anti-tumor effects (Patent Documents 2 to 24 and 31 to 48).

[0004] It has also been disclosed that CCR8 is expressed in the tumor cells themselves in many blood cancers and melanomas (Patent Documents 25 and 26, Non-Patent Documents 9 to 11). However, the therapeutic effect of anti-CCR8 antibodies on cancers in which CCR8 is expressed in tumor cells has not been specifically demonstrated as experimental results to date.

[0005] Bispecific antibodies that recognize both tumor cell surface markers and effector cell surface markers are known to be useful in cancer therapy (Non-Patent Document 12). These bispecific antibodies bind target cells to effector cells, thereby causing the effector cells to exhibit strong cytotoxic activity against the target cells. Examples of bispecific antibodies that recognize CD3, a surface marker for T cells, are disclosed in Patent Documents 27 to 29. Furthermore, an example of a bispecific antibody that recognizes CD16, a surface marker for NK cells, is disclosed in Patent Document 30.

[0006] However, it has not been shown so far that a bispecific antibody recognizing CCR8 as an antigen is useful for cancer therapy. Furthermore, it has not been shown so far that a bispecific antibody recognizing a surface marker of tumor-infiltrating Treg cells and a surface marker of effector cells is useful for cancer therapy. A bispecific antibody recognizing CCR8 as an antigen is described in Patent Document 20, but its pharmacological activity is not disclosed at all.

[0007] U.S. Patent No. 10,087,259 International Publication No. WO 2018 / 181425 International Publication No. WO 2018 / 112032 International Publication No. WO 2020 / 138489 International Publication No. WO 2021 / 142002 International Publication No. WO 2021 / 152186 International Publication No. WO 2021 / 163064 International Publication No. WO 2021 / 178749 International Publication No. WO 2021 / 194942 International Publication No. WO 2021 / 260208 International Publication No. WO 2021 / 260209 International Publication No. WO 2021 / 260210 International Publication No. WO 2022 / 042690 International Publication No. WO 2022 / 078277 International Publication No. WO 2022 / 081718 International Publication No. WO 2022 / 117569 International Publication No. WO 2022 / 136647 International Publication No. WO 2022 / 136649 International Publication No. WO 2022 / 136650 International Publication No. WO 2022 / 256563 International Publication No. WO 2022 / 268192 International Publication No. WO 2023 / 288241 International Publication No. WO 2023 / 010054 International Publication No. WO 2023 / 02062 International Publication No. 1, International Publication No. 2022 / 200303, International Publication No. 2013 / 131010, International Publication No. 99 / 54440, International Publication No. 2016 / 182751, International Publication No. 2017 / 134158, International Publication No. 2020 / 081841, International Publication No. 2023 / 098888, International Publication No. 2023 / 116880, International Publication No. 2023 / 137466, International Publication No. 2023 / 174396, International Publication No. 2023 / 193732, International Publication No. 2023 / 206350 International Publication No. WO 2023 / 208182 International Publication No. WO 2024 / 008110 International Publication No. WO 2024 / 040216 International Publication No. WO 2024 / 059909 International Publication No. WO 2024 / 062019 International Publication No. WO 2024 / 062072 International Publication No. WO 2024 / 062076 International Publication No. WO 2024 / 062082 International Publication No. WO 2024 / 076514 International Publication No. WO 2024 / 086684 International Publication No. WO 2024 / 088346 International Publication No. WO 2024 / 094003

[0008] J. Immunol., 1996, Vol. 157, No. 7, pp. 2759-63; J. Biol. Chem., 1997, Vol. 272, No. 28, pp. 17251-4; Cancer Res., 2016, Vol. 76, No. 4, Supp. 1, P4-04-11; Immunity, 2016, Vol. 45, pp. 1122-1134; Immunity, 2016, Vol. 45, pp. 1135-1147; Proc. Natl. Acad. Sci. USA, 2018, Vol. 115, No. 45, pp. 10672-10681. Targeting of CCR8 induces antitumor activity as a monotherapy that is further enhanced in combination with a Listeria-based immunotherapy, ASCO 2018, Daniel O. Villarreal, et al. https: / / www.advaxis.com / wp-content / uploads / 2018 / 04 / KeystonePosterCCR8-combo-posterFINAL.pdfCancer Res., 2018, Vol. 78, No. 18, pp. 5340-5348Leuk. Lymphoma., 2006, Vol. 47, No. 10, pp. 2163-73Appl. Immunohistochem. Mol. Morphol., 2015, Vol. 23, No. 8, pp. 580-589Modern Pathology, 2013, Vol. 26, pp. 182-194Exp. Hematol., 2021, 10:56

[0009] An object of the present invention is to provide a bispecific antibody that recognizes CCR8 as an antigen, and further to provide a bispecific antibody that recognizes CCR8 as an antigen that is useful for treating and preventing cancer.

[0010] As a result of extensive research, the present inventors have discovered a bispecific antibody that recognizes CCR8 as an antigen. Furthermore, they have found that the bispecific antibody of the present invention that recognizes CCR8 as an antigen exhibits antitumor effects. That is, the bispecific antibody of the present invention that recognizes CCR8 as an antigen is useful for the treatment and prevention of cancer.

[0011] The present invention relates to the following: (1) A bispecific antibody comprising an anti-CCR8-scFv region comprising a light chain variable region and a heavy chain variable region of an anti-CCR8 antibody, and a region comprising one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell. (2) The anti-CCR8-scFv region comprises: 1) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR2 consisting of the amino acid sequence of SEQ ID NO: 58, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 59, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 60, CDR2 consisting of the amino acid sequence of SEQ ID NO: 61, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 62; 2) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR2 consisting of the amino acid sequence of SEQ ID NO: 63, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 59, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 64, CDR2 consisting of the amino acid sequence of SEQ ID NO: 61, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 65; 3) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 66, CDR2 consisting of the amino acid sequence of SEQ ID NO: 67, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 68, and a CDR1 consisting of the amino acid sequence of SEQ ID NO: 69, 3) a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 72, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 67, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 73, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 74, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 75, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 76; or 4) a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 72, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 67, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 73, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 74, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 75, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 76; or 5) a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 77, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 78, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 79, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 80, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 81, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 82.(3) The bispecific antibody according to (1), wherein the anti-CCR8-scFv region comprises: 1) a light chain variable region having the amino acid sequence of SEQ ID NO: 45, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 46; 2) a light chain variable region having the amino acid sequence of SEQ ID NO: 47, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 48; 3) a light chain variable region having the amino acid sequence of SEQ ID NO: 49, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50; 4) a light chain variable region having the amino acid sequence of SEQ ID NO: 51, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 52; 5) a light chain variable region having the amino acid sequence of SEQ ID NO: 53, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 54; or 6) a light chain variable region having the amino acid sequence of SEQ ID NO: 55, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 56. (4) The bispecific antibody according to any one of (1) to (3), wherein in the anti-CCR8-scFv region, the light chain variable region and the heavy chain variable region are linked via the linker sequence of SEQ ID NO: 2. (5) The bispecific antibody according to any one of (1) to (4), wherein a CD8A signal sequence region is linked to the N-terminus. (6) The bispecific antibody according to (5), wherein the CD8A signal sequence region is present on the N-terminal side of the anti-CCR8-scFv region. (7) The bispecific antibody according to (5) or (6), wherein the CD8A signal sequence region has the amino acid sequence of SEQ ID NO: 1. (8) The bispecific antibody according to any one of (1) to (7), wherein the anti-CCR8-scFv region has the amino acid sequence of any one of SEQ ID NOs: 39 to 44. (9) The bispecific antibody according to any one of (1) to (8), wherein the effector cell is a T cell. (10) The bispecific antibody according to (9), wherein the T cell surface marker is CD3 and the bispecific antibody comprises an anti-CD3-scFv region comprising a light chain variable region and a heavy chain variable region of an antibody that recognizes CD3.(11) The anti-CD3-scFv region comprises: 1) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 16, CDR2 consisting of the amino acid sequence of SEQ ID NO: 17, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 18, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 19, CDR2 consisting of the amino acid sequence of SEQ ID NO: 20, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 21; 2) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 22, CDR2 consisting of the amino acid sequence of SEQ ID NO: 23, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 24, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 25, CDR2 consisting of the amino acid sequence of SEQ ID NO: 26, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 27; 3) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR2 consisting of the amino acid sequence of SEQ ID NO: 29, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 30, and a CDR1 consisting of the amino acid sequence of SEQ ID NO: 31, 3) a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 87, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 88, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 89, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 90, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 91, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 92. (12) The bispecific antibody according to (10), wherein the anti-CD3-scFv region comprises: 1) a light chain variable region having the amino acid sequence of SEQ ID NO: 10, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 11; 2) a light chain variable region having the amino acid sequence of SEQ ID NO: 12, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 13; 3) a light chain variable region having the amino acid sequence of SEQ ID NO: 14, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 15; or 4) a light chain variable region having the amino acid sequence of SEQ ID NO: 85, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 86.(13) The bispecific antibody according to (10), wherein the anti-CD3-scFv region has the amino acid sequence of SEQ ID NO: 7, 8, 9, or 84. (14) The bispecific antibody according to (9), wherein the T cell surface marker is CD3 and the bispecific antibody comprises an anti-CD3-VHH region comprising a heavy chain variable region of a VHH antibody that recognizes CD3. (15) The bispecific antibody according to any one of (1) to (8), wherein the effector cell is a NK cell. (16) The bispecific antibody according to (15), wherein the NK cell surface marker is CD16 and the bispecific antibody comprises an anti-CD16-scFv region comprising a light chain variable region and a heavy chain variable region of an antibody that recognizes CD16. (17) The bispecific antibody according to (15), wherein the NK cell surface marker is CD16 and the bispecific antibody comprises an anti-CD16-VHH region comprising a heavy chain variable region of a VHH antibody that recognizes CD16. (18) The bispecific antibody according to (17), wherein the anti-CD16-VHH region comprises a heavy chain variable region comprising: CDR1 consisting of the amino acid sequence of SEQ ID NO: 35, CDR2 consisting of the amino acid sequence of SEQ ID NO: 36, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 37. (19) The bispecific antibody according to (17), wherein the anti-CD16-VHH region has the amino acid sequence of SEQ ID NO: 34. (20) The bispecific antibody according to any one of (1) to (19), wherein an anti-CCR8-scFv region comprising a light chain variable region and a heavy chain variable region of an anti-CCR8 antibody and a region comprising one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell are linked via an scFv linker sequence of any one of SEQ ID NOs: 3 to 6. (21) The bispecific antibody according to any one of (1) to (20), wherein a histidine tag having the amino acid sequence of SEQ ID NO: 38 is attached to the C-terminus. (22) The bispecific antibody according to any one of (1) to (21), which has an Fc region. (23) A pharmaceutical composition comprising the bispecific antibody according to any one of (1) to (22). (24) The pharmaceutical composition according to (23), which is used to treat cancer. (25) The pharmaceutical composition according to (24), which has an effect of removing tumor-infiltrating Treg cells that express CCR8. (26) The pharmaceutical composition according to (24), which is used to treat cancer in which CCR8 is not expressed in tumor cells. (27) The pharmaceutical composition according to (24), which is used to treat cancer in which CCR8 is expressed in tumor cells.(28) A polynucleotide encoding the amino acid sequence of the bispecific antibody according to any one of (1) to (22). (29) An expression vector comprising the polynucleotide according to (28).

[0012] The bispecific antibody of the present invention that recognizes CCR8 as an antigen has an antitumor effect and is therefore very useful as a pharmaceutical, particularly as a pharmaceutical for treating and preventing cancer.

[0013] Cytotoxic activity of CCR8-CD3 bispecific antibodies against human CCR8-expressing cells using PBMCs as effector cells. Evaluation was performed using human CCR8-expressing Rat-1 cells (hCCR8 / Rat-1 cells) as target cells. Cytotoxic activity of CCR8-CD3 bispecific antibodies against human CCR8-expressing cells using unstimulated PBMCs as effector cells. Evaluation was performed using firefly luciferase-expressing hCCR8 / Rat-1 cells (hCCR8 / FLuc / Rat-1 cells) as target cells. Concentration-dependent cytotoxic activity of CCR8-CD3 bispecific antibodies against human CCR8-expressing cells using CD8-positive T cells as effector cells. Evaluation was performed using hCCR8 / FLuc / Rat-1 cells as target cells. Analysis of Foxp3 and CCR8 expression in human adult T-cell leukemia-lymphoma (ATLL) cell lines. ATN-1 cells were used as the ATLL cell line. The cytotoxic activity of the CCR8-CD3 bispecific antibody against ATLL cell lines was evaluated using CD8-positive T cells as effector cells. Firefly luciferase-expressing ATN-1 cells (FLuc / ATN-1 cells) were used as target cells. In the figure, "B1," "B2," "B3," "B4," "B5," and "B6" represent B1-CD3-1, B2-CD3-1, B3-CD3-1, B4-CD3-1, B5-CD3-1, and B6-CD3-1 of the CCR8-CD3 bispecific antibody, respectively. The concentration-dependent cytotoxic activity of the CCR8-CD3 bispecific antibody against ATLL cell lines was evaluated using CD8-positive T cells as effector cells. FLuc / ATN-1 cells were used as target cells. The NFAT activation ability of CCR8-CD3 bispecific antibodies was evaluated using Jurkat cells as effector cells. FLuc / ATN-1 cells were used as target cells. Because the Jurkat cells were transfected with a gene in which the Lucia luciferase gene was linked downstream of the NFAT promoter, Lucia luciferase was expressed upon NFAT activation. The cytotoxic activity of CCR8-CD3 bispecific antibodies with different anti-CD3-scFv regions against human CCR8-expressing cells was evaluated using PBMC as effector cells. hCCR8 / FLuc / Rat-1 cells were used as target cells.Cytotoxic activity of CCR8-CD3 bispecific antibodies with different scFv linker lengths against human CCR8-expressing cells using PBMCs as effector cells was evaluated using hCCR8 / FLuc / Rat-1 cells as target cells. Cytotoxic activity of CCR8-CD3 bispecific antibodies against mature Treg cells using CD8-positive T cells as effector cells was evaluated using mature Treg cells obtained by expanding naive Treg cells isolated from human PBMCs as target cells. In the figure, "B5" and "B6" represent the CCR8-CD3 bispecific antibodies B5-CD3-1 and B6-CD3-1, respectively. Cytotoxic activity of CCR8-CD3 bispecific antibodies against human tumor-infiltrating Treg cells using CD8-positive T cells as effector cells was evaluated using tumor-infiltrating cells from ovarian cancer patients as target cells, and the cells were collected after the assay and analyzed by flow cytometry. In the figure, "B5" and "B6" represent the CCR8-CD3 bispecific antibodies B5-CD3-1 and B6-CD3-1, respectively. The cytotoxic activity of CCR8-CD3 bispecific antibodies against CD8-positive T cells, using CD8-positive T cells as effector cells, was evaluated by using tumor-infiltrating cells derived from an ovarian cancer patient as target cells, recovering the cells after the assay, and performing flow cytometry analysis. In the figure, "B5" and "B6" represent the CCR8-CD3 bispecific antibodies B5-CD3-1 and B6-CD3-1, respectively. The cytotoxic activity of CCR8-CD3 bispecific antibodies against CD4-positive T cells, using CD8-positive T cells as effector cells, was evaluated by using tumor-infiltrating cells derived from an ovarian cancer patient as target cells, recovering the cells after the assay, and performing flow cytometry analysis. In the figure, "B5" and "B6" refer to the CCR8-CD3 bispecific antibodies B5-CD3-1 and B6-CD3-1, respectively. Cytotoxic activity of CCR8-CD16 bispecific antibodies against human CCR8-expressing cells, using human peripheral blood-derived NK cells as effector cells, was evaluated using hCCR8 / FLuc / Rat-1 cells as target cells.In the figure, "B1," "B2," "B3," "B4," "B5," and "B6" represent the CCR8-CD16 bispecific antibodies B1-CD16-VHH, B2-CD16-VHH, B3-CD16-VHH, B4-CD16-VHH, B5-CD16-VHH, and B6-CD16-VHH, respectively. The cytotoxic activity of CCR8-CD16 bispecific antibodies against ATLL cell lines was evaluated using KHYG-1 cells, a human NK cell line, as effector cells. ATN-1 cells were used as target cells. The cytotoxic activity of CCR8-CD16 bispecific antibodies against mature Treg cells was evaluated using KHYG-1 cells, a human NK cell line, as effector cells. Mature Treg cells obtained by expanding naive Treg cells isolated from human PBMCs were used as target cells. Cytotoxic activity against hCCR8 / Rat-1 cells and Rat-1 cells that do not express CCR8, using KHYG-1 cells, a human NK cell line, as effector cells. Cytotoxic activity of a CCR8-CD3 bispecific antibody comprising an anti-mouse CD3-scFv region against human CCR8-expressing cells, using mouse spleen-derived CD8-positive T cells as effector cells. Evaluation was performed using hCCR8 / FLuc / Rat-1 cells as target cells. Cytotoxic activity of a CCR8-CD3 bispecific antibody comprising an anti-mouse CD3-scFv region against human CCR8-expressing cells, using mouse spleen-derived CD8-positive T cells as effector cells. Evaluation was performed using hCCR8 / FLuc / Rat-1 cells as target cells. The activity is shown as specific activity, with the maximum killing rate taken as 100%. Antitumor activity of a CCR8-CD3 bispecific antibody containing an anti-mouse CD3-scFv region, using mouse spleen-derived CD8-positive T cells as effector cells, in mice transplanted with hCCR8 / Fluc / Rat-1 cells. Luminescence intensity reflects the number of hCCR8 / Fluc / Rat-1 cells. Luminescence imaging data shows the antitumor activity in mice transplanted with hCCR8 / Fluc / Rat-1 cells, to which PBMCs and a CCR8-CD3 bispecific antibody were intraperitoneally administered. Antitumor activity of a CCR8-CD3 bispecific antibody, using PBMCs as effector cells, in mice transplanted with hCCR8 / Fluc / Rat-1 cells. Luminescence intensity reflects the number of hCCR8 / Fluc / Rat-1 cells.Luminescence imaging data show the antitumor activity in FLuc / ATN-1 cell-implanted mice to which PBMCs and CCR8-CD3 bispecific antibodies were intraperitoneally administered. Antitumor activity of CCR8-CD3 bispecific antibodies in FLuc / ATN-1 cell-implanted mice using PBMCs as effector cells. Luminescence intensity reflects the number of FLuc / ATN-1 cells. Antitumor activity of CCR8-CD3 bispecific antibodies in FLuc / ATN-1 cell-implanted mice using PBMCs as effector cells. Luminescence intensity reflects the number of FLuc / ATN-1 cells. Cytotoxic activity of CCR8-CD3 bispecific antibodies and CD3-CCR8 bispecific antibodies against ATLL cell lines using PBMCs as effector cells was evaluated using FLuc / ATN-1 cells as target cells. Cytotoxic activity of CCR8-CD3 bispecific antibodies with different scFv linker lengths against human CCR8-expressing cells using PBMC as effector cells. Evaluation was performed using hCCR8 / FLuc / Rat-1 cells as target cells. Cytotoxic activity of CCR8-CD3 bispecific antibodies with Fc regions added thereto using PBMC as effector cells against human CCR8-expressing cells. Evaluation was performed using hCCR8 / FLuc / Rat-1 cells as target cells. Cytotoxic activity of CCR8-CD3 bispecific antibodies with Fc regions added thereto using PBMC as effector cells against ATLL cell lines. Evaluation was performed using FLuc / ATN-1 cells as target cells. Comparison of NF-AT promoter induction activity with CCR8-CD3 bispecific antibodies based on Patent Document 20. Comparison of cytotoxic activity against hCCR8 / FLuc / Rat-1 cells with that of a CCR8-CD3 bispecific antibody based on Patent Document 20. Comparison of cytotoxic activity against FLuc / ATN-1 cells with that of a CCR8-CD3 bispecific antibody based on Patent Document 20.

[0014] Terms used in this specification are used in the sense commonly used in the art unless otherwise specified.

[0015] The bispecific antibody of the present invention comprises an anti-CCR8-scFv region comprising the light chain variable region and heavy chain variable region of an anti-CCR8 antibody, and a region comprising one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell.

[0016] The bispecific antibodies of the present invention can be obtained by determining the entire amino acid sequence based on the amino acid sequence information of an anti-CCR8-scFv region containing the light chain variable region and heavy chain variable region of an anti-CCR8 antibody and a region containing one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell, constructing an expression vector, and expressing the antibody in cells, etc., using the expression vector. Any promoter may be used in the expression vector.

[0017] Examples of cells that can express the bispecific antibodies of the present invention include vertebrate cells such as COS cells, CHO cells, 293 cells, and 293T cells, prokaryotic cells, and yeast. The transformants can be cultured according to methods well known to those skilled in the art, and the bispecific antibodies of the present invention are produced intracellularly or extracellularly within the transformants. The culture medium used for the culture can be appropriately selected from a variety of commonly used medium depending on the host cells used. For example, a medium such as RPMI-1640 medium or Dulbecco's modified Eagle's minimal essential medium (DMEM) supplemented with serum components such as fetal calf serum (FCS) as needed can be used. Antibiotics such as penicillin, streptomycin, and kanamycin may be appropriately added to the medium. For drug selection, selection antibiotics such as geneticin, hygromycin, and puromycin may also be appropriately added. The transformants can be cultured at any temperature that does not significantly reduce the intracellular protein synthesis ability, but culture is preferably carried out at 32 to 42°C, and most preferably at 37°C. If necessary, the cells can be cultured in air containing 1 to 10% (v / v) carbon dioxide.

[0018] Fractions containing the bispecific antibodies of the present invention produced intracellularly or extracellularly as described above can be separated and purified by various known separation procedures that utilize the physical and chemical properties of the protein. Specific examples of such methods include treatment with conventional protein precipitants, various chromatographies such as ultrafiltration, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, and high performance liquid chromatography (HPLC), dialysis, and combinations of these. These methods enable the easy production of bispecific antibodies of the present invention in high yield and with high purity.

[0019] The anti-CCR8-scFv region comprising the light chain variable region and heavy chain variable region of an anti-CCR8 antibody refers to a region that is an scFv fragment derived from an anti-CCR8 antibody and is capable of specifically binding to CCR8, similar to the antibody.

[0020] The region containing one or more variable regions of the light chain or heavy chain of an antibody that recognizes an effector cell surface marker refers to a fragment derived from an antibody that recognizes an effector cell surface marker, which is capable of specifically binding to the effector cell surface marker in the same manner as the antibody. Examples of such a region include, but are not limited to, fragments such as scFv and VHH.

[0021] An scFv is a VH-P-VL or VL-P-VH polypeptide in which one heavy chain variable region (VH) and one light chain variable region (VL) are linked using a suitable linker sequence (hereinafter referred to as P). A VH-P-VL polypeptide is preferred. The VH and VL contained in the scFv used in the present invention may be those of the antibody of the present invention. The scFv used in the present invention can be produced by constructing an scFv expression vector using cDNA encoding the VH and VL of the antibody of the present invention, and introducing it into Escherichia coli, yeast, or animal cells for expression.

[0022] VHH, also known as nanobody, is a heavy chain variable region of an antibody composed only of a heavy chain (VHH antibody) obtained from animals such as camelids, including llamas, camels, and alpacas. The VHH used in the present invention can be produced by constructing a VHH expression vector using cDNA encoding the VHH of the VHH antibody of the present invention, and introducing it into Escherichia coli, yeast, or animal cells for expression.

[0023] CDR-containing peptides, such as scFv and VHH, comprise at least one CDR region of VH or VL. Multiple CDRs can be linked directly or via a suitable linker sequence. The CDR-containing peptides used in the present invention can be produced by constructing CDR-encoding DNA using cDNA encoding the VH and VL of the monoclonal antibody of the present invention, inserting the DNA into an expression vector for animal cells, and expressing the vector in Escherichia coli, yeast, or animal cells. CDR-containing peptides can also be produced by chemical synthesis methods such as the Fmoc method (fluorenylmethyloxycarbonyl method) and the tBoc method (t-butyloxycarbonyl method).

[0024] Specific binding is at least about 1 x 10 -6 The binding activity can be characterized by an equilibrium dissociation constant of 1×10 M or less (e.g., a smaller Kd indicates tighter binding). The Kd value is preferably 1×10 -7 M or less, more preferably 1×10 -8 M or less, more preferably 1×10 -9 M or less. Methods for determining whether two molecules specifically bind are well known in the art and include competitive ELISA, surface plasmon resonance, and the like.

[0025] Anti-CCR8 antibodies can be produced by antibody production techniques known in the art, such as the method described in Immunochemistry in Practice (Blackwell Scientific Publications).

[0026] Genetic engineering techniques known in the art can also be used, such as those described in Molecular Cloning, A Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press (2012) and Current Protocols Essential Laboratory Techniques, Current Protocols (2012).

[0027] The amino acid sequence of human CCR8 is shown in UniProtKB / Swiss-Prot: P51685 (SEQ ID NO: 83). The extramembrane domain of human CCR8 corresponds to an N-terminal region consisting of amino acids 1 to 35, a loop 1 region consisting of amino acids 94 to 107, a loop 2 region consisting of amino acids 172 to 202, and a loop 3 region consisting of amino acids 264 to 280.

[0028] Hybridomas that produce anti-CCR8 antibodies can be prepared using as an immunogen a human CCR8 protein, a gene encoding the full-length human CCR8, human CCR8-expressing cells, etc. When a gene encoding the full-length human CCR8 is used as the immunogen, for example, a hybridoma that produces anti-CCR8 antibodies can be obtained by fusing spleen cells from a mouse that has been DNA-immunized using the gene as an antigen with mouse myeloma cells.

[0029] One embodiment of the anti-CCR8 antibody is a monoclonal antibody having the CDRs or heavy chain variable region / light chain variable region described herein. The antibody or antibody fragment may be derived from any class or subclass of immunoglobulin molecule (e.g., IgG, IgE, IgM, IgD, or IgA; preferably, IgG) and may be obtained from any species, including mouse, rat, shark, rabbit, pig, hamster, camel, llama, goat, or human. The antibody or antibody fragment is preferably a mouse-derived monoclonal antibody or a humanized monoclonal antibody.

[0030] Anti-CCR8 antibodies are characterized by inhibiting the binding of CCR8 to any of CCR8 ligands. The "CCR8 ligand" is not particularly limited as long as it is a substance that binds to CCR8, such as CCL1, CCL8, or CCL18, but is preferably CCL1 or CCL18, and particularly preferably CCL1.

[0031] Regarding the ability to inhibit the binding between CCR8 and a CCR8 ligand, for example, in the case of human CCL1, human CCR8-expressing 293 cells were used, and the Ca 2+ The influx can be determined by measuring the influx and calculating the IC50 value, taking the signal obtained when human CCL1 is not added as an inhibition rate of 100% and the signal obtained when human CCL1 and no antibody are added as an inhibition rate of 0%. The ability to inhibit the binding of other CCR8 ligands can also be determined in the same manner as for human CCL1.

[0032] Human CCL1 has an amino acid sequence shown in UniProtKB / Swiss-Prot No. P22362, etc. Human CCL8 has an amino acid sequence shown in GenBank No. AAI26243.1, etc. Human CCL18 has an amino acid sequence shown in GenBank No. EAW80102.1, etc.

[0033] Anti-CCR8 antibodies also include chimeric, humanized, and fully human antibodies. Humanized monoclonal antibodies have reduced antigenicity in the human body and are therefore useful when administered to humans for therapeutic purposes, etc. Humanized monoclonal antibodies are antibodies in which the complementarity-determining region (CDR) of a non-human mammal, such as a mouse antibody, is grafted onto the framework region (FR) of a human antibody. Therefore, the FR of a humanized monoclonal antibody is of human origin. Appropriate FRs can be selected by referring to the publication by Kabat E. A. et al. In this case, FRs are selected that enable the CDRs to form a good antigen-binding site. If necessary, amino acids in the FR of the antibody variable region may be substituted so that the CDRs of the reshaped humanized monoclonal antibody form an appropriate antigen-binding site (Sato, K. et al., Cancer Res., 1993, vol. 53, p. 851). The proportion of substituted FR amino acids is 0 to 15%, preferably 0 to 5%, of the entire FR region.

[0034] The anti-CCR8 antibody is preferably a CCR8 neutralizing antibody. A CCR8 neutralizing antibody refers to an antibody that has neutralizing activity against CCR8. Whether an antibody has neutralizing activity against CCR8 can be determined, for example, by measuring whether the antibody suppresses the physiological action of any CCR8 ligand (e.g., CCL1) on CCR8.

[0035] The anti-CCR8 antibody is preferably an antibody that strongly recognizes human CCR8. When selecting an antibody that strongly recognizes human CCR8, an antibody or antibody fragment thereof can be selected using the strength of neutralizing activity as an index, thereby selecting an antibody or antibody fragment thereof that more strongly recognizes human CCR8.

[0036] The amino acid sequence of the anti-CCR8-scFv region can be determined using amino acid sequence information of the CDRs or heavy chain variable region / light chain variable region of an anti-CCR8 antibody. The light chain variable region and heavy chain variable region in the anti-CCR8-scFv region may be linked via a linker sequence. An example of the linker sequence is the sequence of SEQ ID NO: 2. Examples of the amino acid sequence of the anti-CCR8-scFv region include the sequences of SEQ ID NOs: 39 to 44.

[0037] The anti-CCR8-scFv region preferably comprises any of the following sequences: 1) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR2 consisting of the amino acid sequence of SEQ ID NO: 58, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 59, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 60, CDR2 consisting of the amino acid sequence of SEQ ID NO: 61, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 62; 2) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR2 consisting of the amino acid sequence of SEQ ID NO: 63, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 59, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 64, CDR2 consisting of the amino acid sequence of SEQ ID NO: 61, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 65; 3) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 66, CDR2 consisting of the amino acid sequence of SEQ ID NO: 67, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 68, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 69, CDR2 consisting of the amino acid sequence of SEQ ID NO: 70, 3) a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 71; 4) a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 72, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 67, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 73, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 74, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 75, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 76; or 5) a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 77, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 78, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 79, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 80, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 81, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 82.

[0038] The anti-CCR8-scFv region more preferably comprises any of the following sequences: 1) a light chain variable region having the amino acid sequence of SEQ ID NO: 45 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 46; 2) a light chain variable region having the amino acid sequence of SEQ ID NO: 47 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 48; 3) a light chain variable region having the amino acid sequence of SEQ ID NO: 49 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50; 4) a light chain variable region having the amino acid sequence of SEQ ID NO: 51 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 52; 5) a light chain variable region having the amino acid sequence of SEQ ID NO: 53 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 54; or 6) a light chain variable region having the amino acid sequence of SEQ ID NO: 55 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 56.

[0039] Examples of effector cells for "regions comprising one or more variable regions of the light chain or heavy chain of an antibody that recognizes a surface marker of an effector cell" include T cells, NK cells, macrophages, etc., with T cells or NK cells being preferred. Examples of surface markers for T cells include immune checkpoint molecules such as CD3, OX40, CD40, 4-1BB, TIGIT, LAG3, GITR, ICOS, and CD28; examples of surface markers for NK cells include CD16, TIGIT, 4-1BB, and LAG3; and examples of surface markers for macrophages include CD64, CD40, and 4-1BB. CD3 or CD16 is preferred as the surface marker for effector cells.

[0040] Examples of amino acid sequences of a region comprising one or more variable regions of the light chain or heavy chain of an antibody that recognizes a surface marker of an effector cell include the sequence of SEQ ID NO: 7 described in Patent Document 27, the sequence of SEQ ID NO: 9 described in Patent Document 28, and the sequence of SEQ ID NO: 8 described in Patent Document 29 when the surface marker is human CD3; the sequence of SEQ ID NO: 84 described in the paper by Fernandes et al. (J. Biol. Chem., (2012), 287(16), 13324-13335) when the surface marker is mouse CD3; and the sequence of SEQ ID NO: 34 described in Patent Document 30 when the surface marker is human CD16.

[0041] The anti-CD3-scFv region is an scFv fragment derived from an antibody that recognizes CD3, and preferably contains any one of the following sequences: 1) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 16, CDR2 consisting of the amino acid sequence of SEQ ID NO: 17, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 18, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 19, CDR2 consisting of the amino acid sequence of SEQ ID NO: 20, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 21; 2) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 22, CDR2 consisting of the amino acid sequence of SEQ ID NO: 23, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 24, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 25, CDR2 consisting of the amino acid sequence of SEQ ID NO: 26, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 27; 3) a light chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR2 consisting of the amino acid sequence of SEQ ID NO: 29, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 30, and a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 31, CDR2 consisting of the amino acid sequence of SEQ ID NO: 32, 3) a heavy chain variable region comprising a CDR3 consisting of the amino acid sequence of SEQ ID NO: 33; or 4) a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 87, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 88, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 89, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 90, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 91, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 92.

[0042] The anti-CD3-scFv region more preferably comprises any of the following sequences: 1) a light chain variable region having the amino acid sequence of SEQ ID NO: 10 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 11; 2) a light chain variable region having the amino acid sequence of SEQ ID NO: 12 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 13; 3) a light chain variable region having the amino acid sequence of SEQ ID NO: 14 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 15; or 4) a light chain variable region having the amino acid sequence of SEQ ID NO: 85 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 86.

[0043] The anti-CD3-VHH region is a VHH fragment derived from a VHH antibody that recognizes CD3.

[0044] The anti-CD16-scFv region is an scFv fragment derived from an antibody that recognizes CD16. The anti-CD16-VHH region is a VHH fragment derived from a VHH antibody that recognizes CD16, and preferably comprises a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of SEQ ID NO: 35, CDR2 consisting of the amino acid sequence of SEQ ID NO: 36, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 37.

[0045] The anti-CD64-scFv region is an scFv fragment derived from an antibody that recognizes CD64, and the anti-CD64-VHH region is a VHH fragment derived from a VHH antibody that recognizes CD64.

[0046] The bispecific antibody of the present invention may comprise a signal sequence region at the N-terminus. The signal sequence is preferably a CD8A signal sequence, and the CD8A signal sequence region may be located on the N-terminal side of the anti-CCR8-scFv region. Furthermore, the CD8A signal sequence region preferably has the amino acid sequence of SEQ ID NO: 1.

[0047] The "anti-CCR8-scFv region comprising the light chain variable region and heavy chain variable region of an anti-CCR8 antibody" and the "region comprising one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell" may be linked via an scFv linker sequence. Examples of scFv linker sequences include the sequences of SEQ ID NOs: 3 to 6.

[0048] The bispecific antibody of the present invention may have a tag attached to the N-terminus or C-terminus, but if a tag is attached, it is preferably attached to the C-terminus. Examples of tags to be attached include histidine, FLAG, glutathione-S-transferase, and hemagglutinin, with a histidine tag being preferred. Furthermore, the histidine tag preferably has the amino acid sequence of SEQ ID NO: 38.

[0049] The bispecific antibody of the present invention preferably comprises, from the N-terminus, a CD8A signal sequence region, an anti-CCR8-scFv region, an scFv linker, a region comprising one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell, and a histidine tag linked in this order.

[0050] The bispecific antibody of the present invention may have an Fc region. The Fc region is preferably a single chain, and preferably has low induction of antibody-dependent cellular cytotoxicity (ADCC) activity, such as the Fc region of a human IgG2 antibody or a human IgG4 antibody, and is preferably inserted immediately before a histidine tag. Antibody mutants mutated to reduce ADCC activity (e.g., human IgG1 antibody mutants) are also preferred as Fc regions. An example of an Fc region is an Fc region having the amino acid sequence of SEQ ID NO: 95.

[0051] Examples of bispecific antibodies of the present invention include, but are not limited to, bispecific antibodies that recognize CCR8 and CD3 as antigens (CCR8-CD3 bispecific antibodies), bispecific antibodies that recognize CCR8 and CD16 as antigens (CCR8-CD16 bispecific antibodies), and bispecific antibodies that recognize CCR8 and CD64 as antigens (CCR8-CD64 bispecific antibodies).

[0052] The respective regions contained in the bispecific antibody of the present invention can exhibit similar effects if their amino acid sequences share 90% or more identity, preferably 95% or more identity.

[0053] The bispecific antibodies of the present invention bind target cells to effector cells, thereby causing the effector cells to exhibit potent cytotoxic activity against the target cells. Note that "cytotoxic activity" includes phagocytic activity by macrophages and the like.

[0054] Examples of CCR8-expressing cells against which the bispecific antibodies of the present invention exhibit cytotoxic activity include Treg cells such as tumor-infiltrating Treg cells, and tumor cells.

[0055] When the CCR8-expressing cells are tumor-infiltrating Treg cells, the tumor is preferably a solid cancer. Specific examples include breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, lung cancer, gastric (gastric adenocarcinoma), non-small cell lung cancer, pancreatic cancer, head and neck squamous cell carcinoma, esophageal cancer, bladder cancer, melanoma, colon cancer, kidney cancer, non-Hodgkin's lymphoma, urothelial cancer, sarcoma, bile duct cancer, gallbladder cancer, thyroid cancer, testicular cancer, thymus cancer, liver cancer, skin cancer, brain tumor, etc. Preferred examples include breast cancer, uterine cancer, ovarian cancer, lung cancer, bladder cancer, colon cancer, kidney cancer, sarcoma, liver cancer, skin cancer, and brain tumor. When the CCR8-expressing cells are tumor-infiltrating Treg cells, CCR8 does not need to be expressed on the tumor cells.

[0056] When the CCR8-expressing cells are tumor cells, the tumor is preferably melanoma or blood cancer. Examples of CCR8-expressing blood cancers include leukemias such as acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL), and lymphomas such as adult T-cell leukemia-lymphoma (ATLL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), diffuse large B-cell lymphoma (DLBCL), and Hodgkin's lymphoma.

[0057] The bispecific antibodies of the present invention are useful as pharmaceutical compositions. The pharmaceutical compositions of the present invention can be administered systemically or locally, orally or parenterally. Parenteral administration can be selected from, for example, intravenous injection such as drip infusion, intramuscular injection, intraperitoneal injection, subcutaneous injection, intranasal administration, and inhalation.

[0058] The pharmaceutical composition of the present invention is extremely useful as a medicament for treating and / or preventing CCR8-related diseases. In particular, it is extremely useful as a medicament for treating and / or preventing cancers in which intratumoral infiltration of CCR8-expressing Treg cells has occurred or cancers in which CCR8 is expressed in tumor cells. For example, it is extremely useful as a medicament for treating and / or preventing cancers such as breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, lung cancer, gastric (gastric adeno) cancer, non-small cell lung cancer, pancreatic cancer, head and neck squamous cell carcinoma, esophageal cancer, bladder cancer, melanoma, colorectal cancer, kidney cancer, non-Hodgkin's lymphoma, urothelial cancer, sarcoma, bile duct cancer, gallbladder cancer, thyroid cancer, testicular cancer, thymic cancer, liver cancer, skin cancer, and brain tumor, preferably breast cancer, uterine cancer, ovarian cancer, lung cancer, bladder cancer, colorectal cancer, kidney cancer, sarcoma, liver cancer, skin cancer, and brain tumor. They are also very useful as pharmaceuticals for treating and / or preventing melanoma, leukemia and lymphoma.

[0059] Cancers according to the present invention include all solid cancers and blood cancers. Specific examples include breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, lung cancer, gastric (gastric adenocarcinoma), non-small cell lung cancer, pancreatic cancer, head and neck squamous cell carcinoma, esophageal cancer, bladder cancer, melanoma, colon cancer, kidney cancer, non-Hodgkin's lymphoma, urothelial cancer, sarcoma, blood cancer (e.g., leukemia, lymphoma), bile duct cancer, gallbladder cancer, thyroid cancer, testicular cancer, thymus cancer, liver cancer, skin cancer, and brain tumor. Preferred examples include breast cancer, uterine cancer, ovarian cancer, lung cancer, bladder cancer, colon cancer, kidney cancer, sarcoma, liver cancer, skin cancer, and brain tumor. Melanoma, leukemia, and lymphoma are also preferred.

[0060] It should be noted that cancer according to the present invention refers not only to epithelial malignant tumors such as ovarian cancer and gastric cancer, but also to non-epithelial malignant tumors including hematopoietic cancers such as chronic lymphocytic leukemia and Hodgkin's lymphoma, and in this specification, the terms "cancer," "carcinoma," "tumor," "neoplasm," etc. are not distinguished from one another and are interchangeable.

[0061] The bispecific antibodies of the present invention may be administered as a concomitant drug in combination with other drugs to: (1) complement and / or enhance the therapeutic effect of the pharmaceutical composition of the present invention; (2) improve the kinetics, absorption, and dosage of the pharmaceutical composition of the present invention; and / or (3) reduce the side effects of the pharmaceutical composition of the present invention.

[0062] A combination of a bispecific antibody of the present invention and another drug may be administered in the form of a combined preparation in which both components are combined in a single formulation, or in the form of separate formulations. Administration in these separate formulations includes simultaneous administration and staggered administration. Staggered administration may involve administering the bispecific antibody of the present invention first and the other drug later, or may involve administering the other drug first and the bispecific antibody of the present invention later, and the administration methods for each may be the same or different.

[0063] It is assumed that the target patients for the pharmaceutical compositions of the present invention are cancer patients or suspected cancer patients. The effective dose of the pharmaceutical composition of the present invention is selected from the range of 0.01 mg to 100 mg per kg of body weight per administration. Alternatively, a dose of 5 to 5,000 mg, preferably 10 to 500 mg, per patient can be selected. However, pharmaceutical compositions containing bispecific antibodies of the present invention are not limited to these doses. Furthermore, the administration period can be appropriately selected depending on the age and symptoms of the patient. The pharmaceutical compositions of the present invention may also contain pharmaceutically acceptable carriers and additives depending on the administration route. Examples of such carriers and additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, sodium alginate, water-soluble dextran, pectin, methylcellulose, ethylcellulose, casein, diglycerin, propylene glycol, polyethylene glycol, petrolatum, human serum albumin (HSA), mannitol, sorbitol, lactose, surfactants acceptable as pharmaceutical additives, and the like. The additives used may be selected appropriately from the above or in combination depending on the dosage form, but are not limited to these.

[0064] The present invention includes polynucleotides encoding the amino acid sequences of the bispecific antibodies of the present invention. The present invention further includes expression vectors comprising the polynucleotides.

[0065] The polynucleotide is not particularly limited as long as it encodes a bispecific antibody of the present invention, and is a polymer composed of multiple nucleotides such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). It may contain non-natural bases. The polynucleotide of the present invention can be used to produce the bispecific antibody of the present invention by genetic engineering techniques.

[0066] The present invention will be described in more detail below with reference to examples of the present invention, but the present invention is not limited to these examples.

[0067] The CDR sequences of each antibody were identified by performing Kabat numbering on the amino acid sequences of the antibody light and heavy chains using antibody sequence analysis software abYsis.

[0068] Antibiotics such as penicillin, streptomycin, and kanamycin were added to each cell culture medium as appropriate.

[0069] Example 1: Preparation of anti-human CCR8 antibody and anti-CCR8-scFv region Anti-human CCR8 antibody was obtained based on the methods described in Examples 1 to 2, 4 to 7, and 9 of WO 2020 / 138489. Furthermore, the heavy chain variable region of the anti-human CCR8 antibody, a G4S peptide linker (SEQ ID NO: 2), and the light chain variable region were linked in this order to prepare an anti-CCR8-scFv region. The SEQ ID NOs for the light chain variable region, heavy chain variable region, and CDRs of the obtained anti-human CCR8 antibody, as well as the SEQ ID NOs for the anti-CCR8-scFv region prepared from each antibody, are shown in Table 1.

[0070] Here, αCCR8-B1 is a humanized monoclonal antibody, αCCR8-B2 to -4 are mouse-derived monoclonal antibodies, and αCCR8-B5 and -B6 are rat-derived monoclonal antibodies. αCCR8-B1, -B4, and -B6 are antibodies described in the Examples of WO2020 / 138489, and αCCR8-B2 and -B3 are antibodies described in the Examples of WO2022 / 211046. The amino acid sequences of the light chain variable region, heavy chain variable region, and CDRs of each antibody are also listed in the sequence listings of the corresponding patent documents listed above and are publicly known.

[0071]

[0072] Example 2: Preparation of bispecific antibodies comprising anti-CCR8-scFv region and anti-CD3-scFv region (1) Anti-CD3-scFv region An anti-CD3-scFv region comprising the light chain variable region and heavy chain variable region of an anti-human CD3 antibody in Table 2 or an anti-mouse CD3 antibody in Table 3 was used to prepare a bispecific antibody.

[0073] The amino acid sequences of the light chain variable region, heavy chain variable region, and anti-CD3-scFv region of the anti-human CD3 antibodies in Table 2 are described in WO99 / 54440 for αCD3-1, in WO2017 / 134158 for αCD3-2, and in WO2016 / 182751 for αCD3-3. The anti-mouse CD3 antibodies in Table 3 are described in a paper by Fernandes et al. (J. Biol. Chem., (2012), 287(16), 13324-13335), and the anti-CD3-scFv region was prepared by linking the heavy chain variable region, G4S peptide linker (SEQ ID NO: 2), and light chain variable region in this order.

[0074]

[0075]

[0076] (2) Preparation of bispecific antibodies Bispecific antibodies comprising an anti-CCR8-scFv region and an anti-CD3-scFv region (CCR8-CD3 bispecific antibodies) were prepared by linking, from the N-terminus, the CD8A signal sequence region (SEQ ID NO: 1), the anti-CCR8-scFv region of Example 1, an scFv linker (SEQ ID NO: 3), the anti-CD3-scFv region of (1), and a histidine tag (SEQ ID NO: 38). When the anti-CD3-scFv region had the sequence of SEQ ID NO: 8, 9, or 84, the sequence of SEQ ID NO: 4 was used as the scFv linker instead of SEQ ID NO: 3.

[0077] Polynucleotides encoding each bispecific antibody were introduced into a mammalian expression vector (a vector in which the CMV promoter of Takara Bio's pQCXIP vector was replaced with a human EF promoter), and 293T cells were transformed using Lipofectamine 3000. Three days after transfection, drug selection was performed with puromycin (1 μg / ml) for one week. The drug-resistant cells were expanded and cultured for an additional two days when the 293T cells became confluent, after which 50 ml of cell culture medium was collected. The collected medium was passed through a 0.45 μm filter and then concentrated using a Millipore Amicon Ultra-4 centrifugal filter (10 kD cutoff). To completely remove puromycin, the concentrated solution was further diluted 10-fold with PBS and then centrifuged three times. The final volume of the solution was concentrated 25-50 times. The amount of bispecific antibody protein contained in this concentrated cell culture medium was quantified using a His-tag ELISA detection kit (GenScript).

[0078] (3) Purification of Bispecific Antibodies The bispecific antibodies prepared in Examples 18-23 were purified using the following method. The cell culture medium after drug selection obtained in (2) was collected and concentrated 35-fold by ultrafiltration using an Amicon Ultra-15 (Millipore) with a 30 kDa cutoff. After concentration, the protein was purified using HIS tag resin (TALON, Takara) according to the manufacturer's protocol. The buffer was then replaced with PBS using the Amicon Ultra-15 and quantified. The resulting protein was quantified using a HIS-TAG quantification kit (HIS tag ELISA detection kit, Genscript) according to the manufacturer's protocol. Western blotting analysis of the resulting bispecific antibodies detected a specific band at the desired size (55 kDa), confirming that the protein could be produced without degradation.

[0079] Example 3: Preparation of bispecific antibodies comprising anti-CCR8-scFv region and anti-CD16-VHH region (1) Anti-CD16-VHH region The anti-CD16-VHH region described in WO2020 / 081841 was used to prepare bispecific antibodies. The anti-CD16-VHH region has the sequence of SEQ ID NO: 34, and CDR1, CDR2, and CDR3 have the sequences of SEQ ID NOs: 35, 36, and 37, respectively.

[0080] (2) Preparation of bispecific antibodies A bispecific antibody comprising an anti-CCR8-scFv region and an anti-CD16-VHH region (CCR8-CD16 bispecific antibody) was prepared in the same manner as in Example 2(2), except that the anti-CD3-scFv region was replaced with an anti-CD16-VHH region. The sequence of SEQ ID NO: 4 was used as the scFv linker.

[0081] Example 4: Cytotoxic activity of CCR8-CD3 bispecific antibodies against human CCR8-expressing cells using PBMCs as effector cells (1) Preparation of effector cells Human peripheral blood mononuclear cells (PBMCs) were stimulated with CD3 / CD28 beads (Dynabeads Human T-activator CD3 / 28, GIBCO) and human IL-2 (Peprotech, final concentration 100 U / ml) for 3 days and stored in an ultra-low temperature freezer. These cells were then awakened and stimulated for an additional 5 days under the same conditions for proliferation. The cells were then divided into two groups. To one group, the beads were removed, and IL-2 alone was added at 100 U / ml and cultured for an additional 24 hours. To the other group, the beads were not removed, and the stimulated cells were further cultured in the presence of IL-2 for an additional 24 hours. These cells were washed twice with assay buffer (4% FCS / DMEM (phenol red-free)) and used for cytotoxic activity evaluation.

[0082] (2) Preparation of target cells: Rat-1 cells (hCCR8 / Rat-1) expressing the human CCR8 gene under the control of a CMV promoter and their parent cells, Rat-1 cells, were used. These cells were cultured in a 10% FCS / DMEM culture medium. Both cells were cultured at 1 x 10 6 Calcein was added at a concentration of 1 / ml to label the cells. The cells were incubated at 37°C for 30 minutes and washed twice with assay buffer. These cells were used to evaluate cytotoxic activity.

[0083] (3) Cytotoxic Activity Assessment Cytotoxic activity assessment was carried out using a CCR8-CD3 bispecific antibody having an anti-CCR8-scFv region derived from αCCR8-B1 and an anti-CD3-scFv region derived from αCD3-1 (referred to as B1-CD3-1) as the CCR8-CD3 bispecific antibody.

[0084] Effector cells were 5 × 10 4 / 150 μL / well, target cells 5 × 10 3The CCR8-CD3 bispecific antibody was mixed in a 96-well plate at a final concentration of 1.7 nM or 0 nM per well (150 μL). Five hours later, 35 μL of the cell culture medium was removed, and the amount of calcein in the medium was quantified using a fluorometer. The killing rate (%) was calculated by setting the spontaneous calcein release after five hours for each target cell alone as 0% and the total calcein release after five hours as 100% (N=1).

[0085] The results are shown in Figure 1. Cytotoxicity of hCCR8 / Rat-1 cells was observed only when both effector cells and the CCR8-CD3 bispecific antibody were added. These results demonstrate that the CCR8-CD3 bispecific antibody has cytotoxic activity against target cells in a manner dependent on effector cells and CCR8 expression.

[0086] Example 5: Cytotoxic activity of CCR8-CD3 bispecific antibodies against human CCR8-expressing cells using unstimulated PBMCs as effector cells (1) Preparation of effector cells Human PBMCs (Precision) were cultured with human IL-2 (Peprotech, final concentration 100 U / ml) for 3 days to stabilize the cell state.

[0087] (2) Preparation of Target Cells Rat-1 cells expressing human CCR8 and firefly luciferase genes driven by a CMV promoter (hCCR8 / FLuc / Rat-1 cells) were used.

[0088] (3) Cytotoxic Activity Assessment Cytotoxic activity assessment was carried out using B1-CD3-1 and B5-CD3-1 (bispecific antibodies having an anti-CCR8-scFv region derived from αCCR8-B5 and an anti-CD3-scFv region derived from αCD3-1) as CCR8-CD3 bispecific antibodies. Blinatumomab was used as a negative control.

[0089] Effector cells were 1 × 10 4 / well / 60 μL, target cells were 1 × 10 3The cells were used at a final concentration of 60 μL per well, with an effector cell to target cell ratio (E / T cell ratio) of 10:1. The CCR8-CD3 bispecific antibody was used at a final concentration of 1.6 nM, and blinatumomab at 0.3 nM. Effector cells and target cells suspended in assay buffer were mixed with the CCR8-CD3 bispecific antibody and cultured in a 96-well plate for 24 hours (N=1) or 48 hours (N=2). Then, 140 μL of assay buffer was added, followed by centrifugation, followed by removal of 100 μL of the supernatant, and replacement of the cell culture medium. 50 μL of firefly luciferase substrate (Bio-Glo Luciferase Assay, Promega) was added to the cells, which were then transferred to a white, light-blocking plate. Luciferase activity was measured 15 minutes later. By replacing the cell culture medium, the luciferase protein released into the medium upon cell death could be removed, and only the luciferase activity present in living cells was quantitatively evaluated.

[0090] Effector cells and target cells were mixed, and the killing rate (%) was calculated by defining the luciferase value in the absence of the CCR8-CD3 bispecific antibody as 0% killing rate by the CCR8-CD3 bispecific antibody, and defining complete killing as 100% killing rate.

[0091] The results are shown in Figure 2. When no CCR8-CD3 bispecific antibody was added or when blinatumomab was added, almost no cytotoxic activity was observed at either 24 or 48 hours. On the other hand, B1-CD3-1 and B5-CD3-1 showed cytotoxic activity of nearly 70 to 100% at both times. These results demonstrate that even when unstimulated PBMCs were used, the CCR8-CD3 bispecific antibody exhibits cytotoxic activity against target cells in an anti-CCR8-scFv region-dependent manner.

[0092] Example 6: Cytotoxic activity of CCR8-CD3 bispecific antibodies against human CCR8-expressing cells using CD8-positive T cells as effector cells (1) Preparation of effector cells Effector cells were prepared from human frozen PBMCs (ACCUCELL) using MojoSort TMCD8-positive T cells were isolated using the Human CD8 T Cell Isolation Kit (BioLegend) according to the protocol. These cells were stimulated for 8 days with Dynabeads Human T-Activator CD3 / CD28 (GIBCO) and human IL-2 (100 U / ml). The beads were added at a 1:5 ratio. The stimulated cells were cryopreserved and used for each subsequent experiment. The cells were then woken up, the beads were removed with a magnet, and the cells were cultured with IL-2 (100 U / ml) for 5 days.

[0093] (2) Evaluation of cytotoxic activity The target cells used were the same hCCR8 / FLuc / Rat-1 cells as the target cells in Example 5. The bispecific antibodies shown in Table 4 were used as CCR8-CD3 bispecific antibodies to evaluate cytotoxic activity.

[0094] Effector cells were 3 × 10 4 / well / 60 μL, target cells were 3 × 10 3 The cells were used in a volume of 60 μL per well, with an effector cell to target cell ratio (E / T cell ratio) of 10:1. The CCR8-CD3 bispecific antibody was evaluated at a concentration of 15.9 pM followed by a 3-fold dilution series (N=2). Each cell and the CCR8-CD3 bispecific antibody were mixed and cultured at 37°C for 6 hours. The cells were washed in the same manner as in Example 5, and the luciferase activity of the cells was measured in the same manner. The killing rate was also calculated in the same manner as in Example 5.

[0095] The results are shown in Figure 3. Furthermore, the EC50 value was calculated from the average of two measurements at each concentration. The analysis was performed using the drc package (Analysis of Dose-Response Curves) in R software. EC50 values ​​were estimated using three-variable log-logistic analysis. The maximum killing rate was also estimated using the same package. As a result, as shown in Table 5, the EC50 values ​​of B2-CD3-1, B3-CD3-1, and B6-CD3-1 were similar, while those of B1-CD3-1 and B5-CD3-1 were higher, with B4-CD3-1 being the highest. The maximum killing rate at the 6-hour assay time showed a similar trend to the EC50 values.

[0096]

[0097]

[0098] Example 7: Cytotoxic activity of CCR8-CD3 bispecific antibodies against ATLL cell lines (1) Analysis of Foxp3 and CCR8 expression in ATLL cell line ATN-1 cells. Human adult T-cell leukemia-lymphoma (ATLL) cell line ATN-1 cells were cultured at 1 x 10 5 The cells were seeded at 1 / well in a 96-well plate. HBSS / 2% FCS / 10 mM HEPES buffer containing 1 / 20 volume of Human TruStain FcX (BioLegend) and 1 / 500 volume of LIVE / DEAD (ThermoFisher) was added to each well and allowed to stand at room temperature for 15 minutes. After washing once with HBSS / 2% FCS / 10 mM HEPES buffer, the cells were suspended in 100 μL of the same buffer and stained for 30 minutes at 4°C with Alexa Fluor 700-labeled anti-human CD3 (BioLegend), PE-labeled anti-human CCR8 antibody (BioLegend), or each fluorescently labeled isotype control antibody (BioLegend). After washing twice with HBSS / 2% FCS / 10 mM HEPES buffer, cells were fixed using Foxp3 / Transcription Factor Staining Buffer Set (eBioscience). Cells were stained with APC-labeled anti-FOXP3 antibody (eBioscience) or APC-labeled isotype control antibody (BioLegend) at 4°C for 30 minutes. After washing twice, the expression of each molecule was measured using a flow cytometer.

[0099] The results are shown in Figure 4. ATN-1 cells are CD4-positive T cells, and because they express large amounts of Foxp3, they are thought to be a cancer cell line derived from human Treg cells. Furthermore, it was confirmed that CCR8 is expressed in approximately 90% of ATN-1 cells.

[0100] (2) Evaluation of cytotoxic activity Since ATN-1 cells express both CCR8 and CD3 molecules on the same cell, like human intratumoral Treg cells, it is possible that the CCR8-CD3 bispecific antibody binds to CCR8 and CD3 molecules on the same cell and activates the ATN-1 cells via signals from the CD3 molecules. This raised concerns that cell activation might affect activation of the CMV promoter, etc., or cell proliferation. To eliminate these concerns, the following experiment was carried out.

[0101] The target cells used were FLuc / ATN-1 cells, which were ATN-1 cells stably transfected with a firefly luciferase gene expressed under the control of a CMV promoter. It was confirmed that luciferase activity correlated with cell number, and 5 × 10 3 As effector cells, CD8-positive T cells cultured in the same manner as in Example 6 were used at 5 × 10 4 The antibodies were used at a concentration of 60 μL per well (E / T cell ratio = 10:1) (N = 3). The six types of CCR8-CD3 bispecific antibodies listed in Table 4 were evaluated. All concentrations were set at 175 pM, and the killing rates after 24 hours in the presence and absence of effector cells were calculated in the same manner as in Example 5. For both the presence and absence of effector cells, the value in the absence of bispecific antibody was defined as a killing rate of 0%, and a value in the absence of luciferase activity of 0 was defined as a killing rate of 100%.

[0102] The results are shown in Figure 5. When effector cells were not added, the effect of each CCR8-CD3 bispecific antibody was within a range of approximately ±10% compared to the effect without the bispecific antibody. From these results, it was determined that the bispecific antibody alone did not exhibit or activate cytotoxic activity against target cells, nor did it exhibit increased luciferase gene expression that would activate the CMV promoter. When effector cells were added, a decrease in the number of target cells was observed only when the bispecific antibody was added, and the cytotoxic activity of B2-CD3-1 and B6-CD3-1 was particularly high.

[0103] Next, the concentration of the CCR8-CD3 bispecific antibody was serially diluted 3-fold starting from 530 pM, and the killing rate was evaluated in the same manner.

[0104] The results are shown in Figure 6. B6-CD3-1 was found to have the strongest cytotoxic activity (N = 2). Using the average killing rate values ​​at each concentration, the EC50 value (four-parameter log-logistic analysis) of each CCR8-CD3 bispecific antibody was estimated using the drc package (Analysis of Dose-Response Curves) in R software. The 95% confidence intervals for the EC50 values ​​were estimated using the tfls method in the same package. The maximum killing rate 24 hours after the assay was also estimated using the same package (Table 6). B6-CD3-1 had the lowest EC50 value, significantly lower at 1.88 pM. The other bispecific antibodies had EC50 values ​​more than 30-fold higher than B6-CD3-1. Furthermore, the maximum killing rate at 24 hours was similar for B6-CD3-1 and B2-CD3-1, and was particularly high among the six types. From the above, it was revealed that among the six CCR8-CD3 bispecific antibodies evaluated this time, B6-CD3-1 had the strongest cytotoxic activity.

[0105] This experiment demonstrated that B6-CD3-1 exhibits cytotoxic activity comparable to that of other bispecific antibodies against target cells such as Rat-1 cells that do not express CD3 molecules, but exhibits stronger cytotoxic activity than other bispecific antibodies against target cells such as ATN-1 that express CD3 molecules. These results strongly suggest that, compared with other bispecific antibodies, B6-CD3-1 is more likely to exhibit trans-binding (binding of CCR8 and CD3 molecules between different cells) than cis-binding (binding between CCR8 and CD3 molecules present on the cell membrane of the same cell). This suggests that the CCR8-binding mode of B6-CD3-1 is more likely to bind to CD3 present in trans, and therefore CCR8-expressing Treg cells are more likely to be killed by effector cells. It would be difficult for a person skilled in the art to predict that a combination of anti-CCR8 and anti-CD3 antibody sequences would be such a trans-dominant combination.

[0106]

[0107] (3) Evaluation of target cell activation through signal transduction from CD3 molecules We evaluated whether each CCR8-CD3 bispecific antibody was able to activate cells through signal transduction from CD3 molecules on T cells, and if so, which bispecific antibody had the best activation ability.

[0108] As effector cells, we used human T cell line Jurkat (Jurkat-Luci NFAT Cells Kit, InvivoGen) cells, which have the Lucia luciferase gene linked downstream of the NFAT promoter, allowing the degree of NFAT promoter activation to be evaluated by the activity of the Lucia luciferase gene. As target cells, we used the same FLuc / ATN-1 cells as in (2). These effector cells and target cells (both cells 2 × 10 4 The CCR8-CD3 bispecific antibody was added in a 3-fold dilution series starting from a final concentration of 53 pM (N=3). After 16 hours, Lucia luciferase activity was quantified according to the kit protocol.

[0109] The results are shown in Figure 7. When the activity without the bispecific antibody was taken as 1, the activity of B6-CD3-1 increased 11.4-fold at 53 pM, 5.6-fold at 17.5 pM, and 2.6-fold at 5.8 pM. The other CCR8-CD3 bispecific antibodies showed activity less than 2-fold at any concentration. B6-CD3-1 had higher NFAT activation ability than the other bispecific antibodies, even at a concentration approximately 10-fold lower than the other bispecific antibodies. Furthermore, B2-CD3-1 had the second highest activity after B6-CD3-1, and the cytotoxic activity and NFAT activation ability of each bispecific antibody were approximately positively correlated. Furthermore, a significance test (T-test) was performed between B6-CD3-1, the other CCR8-CD3 bispecific antibodies, and no bispecific antibody at each bispecific antibody concentration. As a result, across all concentration ranges, B6-CD3-1 was significantly different from other CCR8-CD3 bispecific antibodies and no bispecific antibody (significance levels: 0.01 at 53 pM, 0.001 at 17.5 pM, and 0.05 at 5.8 pM). These results demonstrate that B6-CD3-1 is superior in both cytotoxic activity and ability to activate NFAT from CD3.

[0110] Example 8: Optimization of amino acid sequence of anti-CD3-scFv region in CCR8-CD3 bispecific antibody B6-CD3-2 and B6-CD3-3 in Table 7 were prepared by replacing the anti-CD3-scFv region of B6-CD3-1.

[0111]

[0112] The target cells were the hCCR8 / FLuc / Rat-1 cells (5 x 10 3 PBMC cells activated in the same manner as in Example 4 were mixed as effector cells in a 96-well plate at an E / T cell ratio of 3:1, and each CCR8-CD3 bispecific antibody in Table 7 was added in a 3-fold dilution series starting from 17.1 pM for B6-CD3-1, 15.9 pM for B6-CD3-2, and 15.9 pM for B6-CD3-3. The killing rate was calculated in the same manner as in Example 7.

[0113] The results are shown in Figure 8. Concentration-dependent cytotoxic activity was observed regardless of which CCR8-CD3 bispecific antibody was used. The EC50 value, its 95% confidence interval, and the maximum killing rate at 6 hours were estimated by three-variable log-logistic analysis as in Example 7 (Table 8). As a result, the 95% confidence interval for the EC50 value of B6-CD3-1 did not overlap with the 95% CI for B6-CD3-2, and therefore it was determined that there was a significant difference between the EC50 values ​​of the two. From the above, it was found that B6-CD3-1 had the highest cytotoxic activity.

[0114]

[0115] Example 9: Positional optimization of anti-CCR8-scFv region and anti-CD3-scFv region in CCR8-CD3 bispecific antibody (1) To optimize the relative positions of the anti-CCR8-scFv region and anti-CD3-scFv region in the CCR8-CD3 bispecific antibody, B6-CD3-1 was prepared using the sequence of SEQ ID NO: 5 (1xP linker) or SEQ ID NO: 6 (6xP linker) as the scFv linker instead of the sequence of SEQ ID NO: 3 (B6-1xP-CD3-1, B6-6xP-CD3-1).

[0116] The cytotoxic activity of B6-1×P-CD3-1, B6-6×P-CD3-1, and B6-CD3-1 was evaluated by the following method. The hCCR8 / FLuc / Rat-1 cells (5×10 3 PBMC cells activated in the same manner as in Example 4 were mixed as effector cells in a 96-well plate at an E / T cell ratio of 20:1, and the above-mentioned CCR8-CD3 bispecific antibodies were added in a 5-fold dilution series starting from 159 pM for B6-CD3-1, 150 pM for B6-1×P-CD3-1, and 153 pM for B6-6×P-CD3-1 (N=3). After 16 hours, the medium was replaced in the same manner as in Example 5, and a luciferase assay was performed. The killing rate was calculated in the same manner as in Example 7, with the killing rate in the absence of bispecific antibody being set to 0%.

[0117] The results are shown in Figure 9. Furthermore, the EC50 value, its 95% confidence interval, and the maximum killing rate at 6 hours were estimated by the same three-variable log-logistic analysis as in Example 7 (Table 9). It was found that B6-CD3-1 had the highest cytotoxic activity, and that the relative positions of the CCR8 and CD3 antibody regions were the most optimal. B6-1xP-CD3-1 and B6-6xP-CD3-1 showed reduced activity. These results demonstrate that B6-CD3-1 has the optimal length between the anti-CCR8-scFv region and the anti-CD3-scFv region.

[0118]

[0119] Example 10: Cytotoxic activity of CCR8-CD3 bispecific antibodies against mature Treg cells (1) Preparation of mature Treg cells PBMCs were isolated from human peripheral blood using Ficoll-Paque PLUS (GEW Healthcare), and CD4+ cells were purified using a CD4+ T Cell Isolation Kit human (Miltenyi Biotec). Naive Treg cells (CD127-negative, CD4 / CD45RA / CD25-positive fraction) were isolated from CD4-positive cells using FITC-labeled anti-human CD4, PerCP_Cy5.5-labeled anti-human CD45RA, PECy7-labeled anti-human CD25, and Bv510-labeled anti-human CD127 antibodies using a FACS Aria (BD Bioscience). The isolated naive Treg cells were expanded and cultured according to the Dynabeads Human Treg Expander (Veritas) protocol to prepare mature Treg cells.

[0120] CCR8 expression on the cell surface of mature Treg cells was measured using an anti-human CCR8 antibody with a flow cytometer, and the CCR8-positive rate among the induced mature Treg cells was found to be 50%.

[0121] (2) Preparation of effector cells: PBMCs were isolated from human peripheral blood using Ficoll-Paque PLUS (GEW Healthcare), and CD8+ T cells were purified using a CD8+ T Cell Isolation Kit for human (Miltenyi Biotec). These cells were used as fresh effector cells in the assay.

[0122] In addition, isolated CD8+ T cells were cultured for 10 days in RPMI1640 / 10% FCS medium at 37°C and 5% CO2 in the presence of 100 U / mL of IL-2 (Shionogi) and Dynabeads Human T-Activator CD3 / CD28 (Veritas). The Dynabeads were then removed, and the cells were cryopreserved using CELLBANKER1 (Xenogen Pharma). Two days before the assay, the frozen cells were awakened and cultured for two days in RPMI1640 / 10% FCS medium supplemented with 100 U / mL of IL-2 at 37°C and 5% CO2, and used as activated effector cells in the assay.

[0123] (3) Cytotoxicity Assessment: 1 × 10 mature Treg cells labeled with Cell Trace Violet (Thermo Fisher Scientific) were used. 4 / well, 1 × 10 effector cells 5 Cells were cultured in 96-well plates at 37°C in 5% CO2 for 24 or 48 hours in RPMI1640 / 10% FCS medium supplemented with 10 U / mL of IL-2 in the presence of CCR8-CD3 bispecific antibodies (B5-CD3-1, B6-CD3-1, both at a final concentration of 530 pM) at 37°C in 5% CO2. After incubation, the cells were washed once with HBSS / 2% FCS / 10 mM HEPES buffer, suspended in 100 μL of the same buffer, and stained with LIVE / DEAD (ThermoFisher) for 30 minutes at 4°C. After washing twice with the same buffer, the number of surviving mature Treg cells was measured using a flow cytometer. The percentage of CCR8-positive cells was calculated based on the percentage of CCR8-positive cells in wells containing only target cells.

[0124] The results are shown in Figure 10. Compared to the control, the cytotoxic activity of B5-CD3-1 and B6-CD3-1 was significantly higher (T-test). From the above, it was confirmed that the CCR8-CD3 bispecific antibody exhibits cytotoxic activity against mature Treg cells expressing CCR8.

[0125] Example 11: Cytotoxic activity of CCR8-CD3 bispecific antibodies against human tumor-infiltrating Treg cells (1) Preparation of human tumor-infiltrating cells Tumor tissue from an ovarian cancer patient was dispersed using a Tumor Dissociation Kit, human (Miltenyi Biotec) to prepare a cell population containing tumor-infiltrating Treg cells, CD8-positive T cells, and CD4-positive T cells other than Treg cells. Cryopreserved cells were used in the experiment.

[0126] (2) Measurement of CCR8-Positive Rate of Human Tumor-Infiltrating Treg Cells The CCR8-positive rate of tumor-infiltrating Treg cells in the cell population obtained in (1) was measured using flow cytometry.

[0127] Human TruStain FcX (BioLegend) and Zombie NIR TM The cells were suspended in HBSS / 2% FCS / 10 mM HEPES buffer supplemented with Fixable Viability Kit (Biolegend) and allowed to stand at 4°C for 30 minutes. After washing, various antibodies were added and allowed to stand at 4°C for 30 minutes (Bv785-labeled anti-human CD45 antibody, AlexaFlour700-labeled anti-human CD3 antibody, Bv711-labeled anti-human CD4 antibody, PE-labeled anti-human CCR8 antibody, PE-Dazzle594-labeled anti-human CD56 antibody, Bv510-labeled anti-human CD8 antibody (all Biolegend)). After washing, the cells were incubated at 4°C for 30 minutes with eBioscience. TM After fixation and membrane permeabilization using Foxp3 / Transcription Factor Staining Buffer Set (Thermo Fisher), APC-labeled anti-human Foxp3 (Thermo Fisher) was added and the cells were incubated at 4°C for 30 minutes. After washing, the CCR8 positivity rate among tumor-infiltrating Treg cells (CD45, CD3, CD4, and Foxp3-positive and Zombie NIR, CD8, and CD56-negative fraction) was measured using a flow cytometer.

[0128] (3) Evaluation of Cytotoxic Activity Human tumor-infiltrating Treg cells derived from ovarian cancer obtained in (2) were used as target cells, and peripheral blood-derived CD8-positive T cells obtained in Example 10 were used as effector cells.

[0129] Effector cells and target cells labeled with CytoTell UltraGreen (AAT BIOQUEST) were plated in a 96-well plate at 1 × 10 5 Cells were seeded at 1000 cells / well and cultured in RPMI1640 / 10% FCS / human IL-2 (100 U / mL) in the presence of CCR8-CD3 bispecific antibodies (B5-CD3-1, B6-CD3-1, both at a final concentration of 530 pM). 24 hours after the start of the evaluation, the cells were harvested and stained with Human TruStain FcX (BioLegend) and Zombie NIR. TM The cells were suspended in HBSS / 2% FCS / 10 mM HEPES buffer supplemented with Fixable Viability Kit (Biolegend) and allowed to stand at 4°C for 30 minutes. After washing, various antibodies were added and allowed to stand at 4°C for 30 minutes (Bv785-labeled anti-human CD45 antibody, AlexaFlour700-labeled anti-human CD3 antibody, PE-Cy7-labeled anti-human CD56 antibody, Bv711-labeled anti-human CD4, Bv510-labeled anti-human CD8 antibody (all Biolegend), and human CCR8 antibody). The human CCR8 antibody used was an APC-labeled CCR8 antibody (Biolegend) when evaluating B5-CD3-1, and an unlabeled CCR8 antibody (ITM) and Alexa647-labeled Donkey Anti-Rat IgG (H+L) when evaluating B6-CD3-1. TM After fixation and membrane permeabilization using Foxp3 / Transcription Factor Staining Buffer Set (Thermo Fisher), PE-labeled anti-human Foxp3 (Thermo Fisher) was added and the plate was left to stand at 4°C for 30 minutes. After washing, the proportions of CCR8-positive Treg cells (CD45, CD3, CD4, Foxp3, CCR8-positive and Zombie NIR, CD8, CD56-negative fraction), CD8-positive T cells, and CD4-positive Tconv cells among viable CD45-positive cells were quantified using a flow cytometer.

[0130] The results are shown in Figure 11. Compared to the control group to which no bispecific antibody was added, a significant decrease in human tumor-infiltrating CCR8-positive Treg cells was observed in the CCR8-CD3 bispecific antibody-added group. The reduction rates for B5-CD3-1 were 71% for donor 1, 91% for donor 2, and 96% for donor 3, and for B6-CD3-1 were 96% for donor 2 and 97% for donor 3 (Dunnett's test, P<0.0005). On the other hand, no significant decrease in CD8-positive T cells was observed in any donor (Figure 12). No significant decrease in CD4-positive T cells was observed in donor 1 or donor 3 (Figure 13). These results confirm that the CCR8-CD3 bispecific antibody has potent cytotoxic activity specifically against tumor-infiltrating Treg cells.

[0131] Example 12: Cytotoxic activity of CCR8-CD16 bispecific antibodies against human CCR8-expressing cells, using human peripheral blood-derived NK cells as effector cells. Using the hCCR8 / Fluc / Rat-1 cells of Example 5, a cytotoxic activity test was carried out using the CCR8-CD16 bispecific antibodies in Table 10.

[0132]

[0133] hCCR8 / Fluc / Rat-1 cells were used as target cells, and human peripheral blood-derived NK cells (BioTherapy Research Institute) were used as effector cells at an E / T cell ratio of 10:1 (effector cells: 1 × 10 5 / well, target cells: 1 x 10 4The cells were mixed with assay buffer to a final concentration of 1000 pM / well and plated on a 96-well plate. Then, CCR8-CD16 bispecific antibody was added to each well to a final concentration of 440 pM. Control wells were set aside without the bispecific antibody. After adding the cells and antibody, the plate was centrifuged at 1,000 rpm for 2 minutes to pellet the cells. After centrifugation, the plate was cultured for 16 hours at 37°C and 5% CO2. After the culture, 100 μL of assay buffer was added, the plate was centrifuged at 1,000 rpm for 2 minutes, and 100 μL of the supernatant was discarded. This washing procedure was repeated three times. Finally, 100 μL of the supernatant was discarded, and 50 μL of luciferin was added. The luminescence intensity of each well was quantified within 30 minutes using a luminometer. Cytotoxic activity was evaluated using luciferase luminescence intensity as an index, and the value in the wells without the bispecific antibody was considered to be undamaged (100% survival), using the following formula: {1 - (luminescence value of wells with bispecific antibody added / luminescence value of wells without bispecific antibody added)} x 100 (%)

[0134] The results are shown in Figure 14. Cytotoxic activity was observed with various CCR8-CD16 bispecific antibodies. In particular, high activity was observed with the CCR8-CD16 bispecific antibody using B1-CD16-VHH and B3-CD16-VHH, suggesting that B1-CD16-VHH has the highest cytotoxic activity. From the above, it was revealed that CCR8-CD16 bispecific antibodies exhibit cytotoxic activity, and that B1-CD16-VHH exhibits the highest cytotoxic activity.

[0135] Example 13: Cytotoxic activity of CCR8-CD16 bispecific antibody against ATLL cell line Using B1-CD16-VHH as the CCR8-CD16 bispecific antibody, the cytotoxic activity against ATN-1 cells, an ATLL cell line, was evaluated.

[0136] Calcein-labeled ATN-1 cells were used as target cells, and KHYG-1 cells, a human NK cell line, were used as effector cells. The E / T cell ratios were 10:1, 3:1, and 1:1 (target cells: 1 × 10 4The cells were mixed with assay buffer at a concentration of 1 / well and seeded into a 96-well plate. B1-CD16-VHH was then added to a final concentration of 4.4 nM. Control wells were set aside without the bispecific antibody. After adding the cells and antibody, the plate was centrifuged at 1,000 rpm for 2 minutes to allow the cells to settle. After centrifugation, the cells were cultured for 2 hours at 37°C and 5% CO2. After the culture, 50 μL of assay buffer was added, and 70 μL of the cell supernatant was aliquoted. The fluorescence level of the aliquoted supernatant was quantified using a fluorometer. The spontaneous release of calcein from ATN-1 cells (BG) was determined by similarly measuring the supernatant from wells containing only target cells. The total amount of calcein released (TOTAL) was determined by aliquoting 70 μL of the cell suspension after adding the assay buffer and measuring it. The killing rate, using calcein release as an index, was calculated by the following formula: {(fluorescence value of each well−BG fluorescence value) / ((total fluorescence value−BG fluorescence value)}×100(%). The BG was subtracted, and the killing rate (%) was calculated by setting the fluorescence amount in the supernatant when all the cells were killed as 100%.

[0137] The results are shown in Figure 15. Higher cytotoxic activity was observed in wells to which B1-CD16-VHH was added at a final concentration of 4.4 nM, compared to the control. These results demonstrate that the CCR8-CD16 bispecific antibody exhibits cytotoxic activity against ATLL cell lines.

[0138] Example 14: Cytotoxic activity of CCR8-CD16 bispecific antibody against mature Treg cells

[0112] Using B1-CD16-VHH as a CCR8-CD16 bispecific antibody, it was examined whether or not the antibody exhibits cytotoxic activity against mature Treg cells induced from human peripheral blood. Cytotoxic activity was evaluated in the same manner as in Example 13, using the mature Treg cells of Example 10 as target cells and the KHYG-1 cells of Example 13 as effector cells.

[0139] The results are shown in Figure 16. Addition of B1-CD16-VHH to a final concentration of 4.4 nM resulted in a higher cytotoxic activity compared to the control. These results demonstrate that the CCR8-CD16 bispecific antibody exhibits cytotoxic activity against mature Treg cells induced from human peripheral blood.

[0140] Example 15: Effect of the presence or absence of CCR8 expression in target cells on the cytotoxic activity of a CCR8-CD16 bispecific antibody Using B1-CD16-VHH as a CCR8-CD16 bispecific antibody, it was examined whether the cytotoxic activity depends on CCR8 expression. Cytotoxic activity was evaluated in the same manner as in Example 13, using the CCR8-expressing Rat-1 cells (hCCR8 / Rat-1 cells) of Example 4 and the non-CCR8-expressing Rat-1 cell line as target cells, and the KHYG-1 cells of Example 13 as effector cells. The killing rate, using calcein release as an index, was calculated by the following formula: {(fluorescence value of each well - fluorescence value of wells to which no bispecific antibody was added) / ((total fluorescence value - fluorescence value of wells to which no bispecific antibody was added)} × 100 (%)

[0141] The results are shown in Figure 17. Increased cytotoxic activity of B1-CD16-VHH was observed in CCR8-expressing cells Rat-1 compared to CCR8-non-expressing Rat-1.

[0142] Example 16: Cytotoxic activity of a CCR8-CD3 bispecific antibody containing an anti-mouse CD3-scFv region against human CCR8-expressing cells, using mouse spleen-derived CD8-positive T cells as effector cells (1) Preparation of mouse spleen-derived CD8-positive T cells Spleens were removed from wild-type mice, passed through a 70 μm filter, and subjected to hemolysis to prepare a cell suspension. CD8-positive T cells were then prepared using a CD8a+ T Cell Isolation Kit (Miltenyi). The obtained CD8-positive T cells were activated by culturing with human IL-2 and anti-mouse CD3 / 28 Dynabeads for at least one day and then used as effector cells.

[0143] (2) Evaluation of Cytotoxic Activity As a CCR8-CD3 bispecific antibody containing an anti-mouse CD3-scFv region, a bispecific antibody (B6-mCD3) having an anti-CCR8-scFv region derived from αCCR8-B6 and an anti-CD3-scFv region derived from αmCD3 was used, and its cytotoxic activity was evaluated in a luciferase assay system.

[0144] The target cells used were the hCCR8 / Fluc / Rat-1 cells of Example 5, and the effector cells were CD8 T cells derived from mouse spleens. The E / T cell ratio was 10:1 (effector cells: 1 × 10 5 / well, target cells: 1 x 10 4 The antibody was mixed with assay buffer at a concentration of 1000 μg / well and seeded into a 96-well plate. B6-mCD3 was then added to each well to a final concentration of 360 pM, 36 pM, or 3.6 pM. Control wells were set up without the addition of the bispecific antibody.

[0145] After adding the cells and antibody, the plates were centrifuged at 1000 rpm for 2 minutes using a plate centrifuge to allow the cells to settle. After centrifugation, the plates were incubated at 37°C and 5% CO for 16 hours. This washing procedure, which involved adding 100 μL of assay buffer, centrifuging at 1000 rpm for 2 minutes, and discarding the supernatant, was repeated three times. Finally, after discarding the supernatant, 50 μL of luciferin was added, and the luminescence of each well was quantified using a luminometer.

[0146] The results are shown in Figure 18-1. When 360 pM of B6-mCD3 was added, cytotoxic activity was observed compared to the control. Furthermore, it was confirmed that the cytotoxic activity changed depending on the bispecific antibody concentration. These results demonstrate that the CCR8-CD3 bispecific antibody containing the anti-mouse CD3-scFv region exhibits cytotoxic activity.

[0147] Furthermore, 50 μL / well of B6-mCD3 was added at final concentrations of 10 pM-10 nM, and cytotoxic activity was evaluated in the same manner as above. The results are shown in Figure 18-2. Concentration-dependent cytotoxic activity was observed in wells to which B6-mCD3 was added compared to the control. The EC50 was calculated to be 62.3 pM.

[0148] Example 17: Antitumor activity of a CCR8-CD3 bispecific antibody comprising an anti-mouse CD3-scFv region, using mouse spleen-derived CD8-positive T cells as effector cells, in mice transplanted with human CCR8-expressing cells. Using the hCCR8 / Fluc / Rat-1 cells of Example 5 as target cells and mouse spleen-derived CD8 T cells as effector cells, the tumor cells were cultured at an E / T cell ratio of 2:1 (effector cells: 7 x 10 6 , target cells: 3.5 x 10 6 The mixture was mixed with 100 μL of PBS to give a total volume of 100 μL, and administered intraperitoneally to NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl / SzJ, Jackson Laboratory). Each mouse was then administered 2 μg of the bispecific antibody (B6-mCD3) at the time of transplantation, and 1 μg each on days 1 and 2 after transplantation. PBS-administered mice served as controls.

[0149] The proliferation of Rat-1 cells in the peritoneal cavity was measured on days 2, 5, and 9 after transplantation. At the time of measurement, 150 μL of a luciferase substrate (D-luciferin, 30 mg / mL) was administered intraperitoneally, and 10 minutes later, the luminescence intensity, which is an index of tumor volume in the peritoneal cavity, was measured using an IVIS Lumina luminescence detection device.

[0150] The results are shown in Figure 19. Antitumor activity was observed in the group administered with B6-mCD3 compared to the control. These results demonstrate that the CCR8-CD3 bispecific antibody containing the anti-mouse CD3-scFv region also exhibits activity in vivo.

[0151] Example 18: Antitumor activity of CCR8-CD3 bispecific antibody in mice transplanted with human CCR8-expressing cells. The hCCR8 / FLuc / Rat-1 cells (3.5 × 10 6 ) were used as effector cells, and human PBMCs (7 × 10 6) was mixed with 200 μL of PBS and administered intraperitoneally to NSG mice. 15 minutes later, B6-CD3-1 (1 μg) dissolved in 200 μL of PBS or 200 μL of PBS as a negative control was administered intraperitoneally (N=4). 2 and 3 days after transplantation, 1 μg of B6-CD3-1 and the control PBS were similarly dissolved in 200 μL of PBS and administered intraperitoneally.

[0152] On days 4, 7, 11, and 15 after transplantation, the luminescence intensity was measured using an IVIS Lumina luminescence detection device in the same manner as in Example 17. The measurement was performed on a body region of the mouse that covered the entire vertical width from the mouth to the base of the tail and the entire horizontal width, and the amount of light emitted in the same area was calculated as Total Flux (photons / second), which is the amount of photons per second.

[0153] The results are shown in Figures 20 and 21. The graph in Figure 21 is a graph of the average luminescence intensity and standard deviation (SD) of four mice in each group. Measurements were performed up to 15 days after transplantation, and significant differences between groups were tested using ANOVA (two-factor mixed design analysis of variance), with significant differences recognized at a significance level of P<0.01. These results demonstrate that the CCR8-CD3 bispecific antibody can kill human CCR8-expressing cells in the peritoneal cavity of mice, and significant anti-tumor activity was observed in mice.

[0154] Example 19: Antitumor activity of CCR8-CD3 bispecific antibody in ATLL cell line-implanted mice. 6 ) were used as effector cells, and human PBMCs (3 × 10 6 ) was mixed with 150 μL of PBS, and 100 μL of ice-cold Matrigel 354230 (Corning) was added, followed by intraperitoneal administration to NSG mice. Subsequently, 150 μL of PBS or B6-CD3-1 (0.75 μg) dissolved in PBS was administered. Furthermore, on days 2 and 3 after transplantation, 200 μL of PBS or 0.75 μg of B6-CD3-1 dissolved in 200 μL of PBS was similarly administered intraperitoneally.

[0155] On days 4, 8 and 11 after transplantation, the luminescence intensity was measured using an IVIS Lumina luminescence detection device in the same manner as in Example 17.

[0156] The results are shown in Figures 22 and 23. The graph in Figure 23-1 is a graph of the mean luminescence intensity and standard deviation (SD) of four mice in each group. Measurements were made up to day 11 after transplantation, and a Student's T test was performed on the mean values ​​on each measurement day to test for significant differences between groups. Significant differences were observed at two points, day 4 and day 11 after transplantation, with a significance level of P<0.05. Furthermore, the area under curve (AUC) between the graph and the X-axis for each mouse was calculated, and the mean area and standard deviation (SD) for each group were calculated, as shown in Figure 23-2. A Mann-Whitney U test was used to test for significant differences between these areas. As a result, a significant difference was observed between the two groups with a significance level of P<0.05. These results demonstrate that the CCR8-CD3 bispecific antibody can kill ATN-1 cells, an ATLL cell line, in the peritoneal cavity of mice, and significant antitumor activity was observed in mice.

[0157] Example 20: Comparison of cytotoxic activity between CCR8-CD3 bispecific antibody and CD3-CCR8 bispecific antibody (1) Preparation of CD3-CCR8 bispecific antibody A CD3-CCR8 bispecific antibody was prepared by swapping the order of the anti-CCR8-scFv region and the anti-CD3-scFv region from a CCR8-CD3 bispecific antibody. Specifically, a CD8A signal sequence region (SEQ ID NO: 1), the anti-CD3-scFv region of αCD3-1 (SEQ ID NO: 7), an scFv linker (SEQ ID NO: 3), the anti-CCR8-scFv region of αCCR8-B6 (SEQ ID NO: 44), and a histidine tag (SEQ ID NO: 38) were linked in this order from the N-terminus to prepare a CD3-CCR8 bispecific antibody (CD3-1-B6) in which the order of the anti-CCR8 antibody region and the anti-CD3 region of B6-CD3-1 were swapped. The protein was prepared and purified in the same manner as in Example 2.

[0158] (2) Evaluation of Cytotoxic Activity The FLuc / ATN-1 cells of Example 7 were used as target cells, and human PBMC cells activated in the same manner as in Example 4 were used as effector cells. Target cells (3 × 10 3Cells (1000 pM / well) were seeded, and effector cells were added to give an E / T cell ratio of 2:1. Furthermore, bispecific antibodies were added to a final concentration of 1000 pM, diluted 3-fold to 1.4 pM. The final volume per well was 150 μL. The assay buffer was DMEM / 4% FCS. After 16 hours, the cells were washed twice with the elimination buffer, and 50 μL of luciferase substrate was added to the cells. After 10 minutes, the luciferase luminescence level per well was measured using a luminometer. The killing rate was calculated in the same manner as in Example 7.

[0159] The results are shown in Figure 24. The EC50 value of CD3-1-B6 was 7.2 pM ± 0.96 pM (standard error), with a 95% confidence interval for the EC50 value of 5.1 pM to 9.3 pM. On the other hand, the EC50 value of B6-CD3-1 was 0.08 pM ± 0.16 pM (standard deviation), with a 95% confidence interval for the EC50 value of -0.27 pM to 0.42 pM. From the above, it was found that CD3-1-B6, in which the order of the scFv regions was changed, had significantly reduced cytotoxic activity compared to B6-CD3-1 in the normal orientation, and that the order of the anti-CCR8-scFv region, followed by the anti-CD3-scFv region, resulted in higher cytotoxic activity.

[0160] Example 21: Positional optimization of anti-CCR8-scFv region and anti-CD3-scFv region in CCR8-CD3 bispecific antibody (2) To determine whether the distance between the scFv regions of a CCR8-CD3 bispecific antibody affects cytotoxic activity and what the optimal distance is, B6-L1-CD3-1 was prepared, in which an ANAS+4xG4S linker (SEQ ID NO: 93) was inserted between the anti-CCR8-scFv region and the anti-CD3-scFv region. The protein was prepared and purified in the same manner as in Example 2. Note that B6-CD3-1 has one G4S inserted.

[0161] The cytotoxic activity of B6-CD3-1 and B6-L1-CD3-1 was evaluated in the same system as in Example 20, and the results are shown in Figure 25. The EC50 values ​​of B6-CD3-1 and B6-L1-CD3-1 were 0.54 pM ± 0.12 pM (standard error) and 0.91 pM ± 0.24 pM (standard error), respectively, with B6-CD3-1 having a lower EC50 value.

[0162] Example 22: Cytotoxic activity of CCR8-CD3 bispecific antibody having an Fc region added A bispecific antibody was prepared by attaching a single-chain Fc region to the C-terminus of a CCR8-CD3 bispecific antibody. The Fc region is the Fc region of the bispecific antibody described in Patent Document 29 and has the amino acid sequence of SEQ ID NO: 95. B6-CD3-1-Fc was prepared by inserting, in this order, the GSGGGG linker of SEQ ID NO: 94 and the Fc region of SEQ ID NO: 95 between the anti-CD3-scFv region and the histidine tag of B6-CD3-1. The protein was prepared and purified in the same manner as in Example 2.

[0163] The cytotoxic activity of B6-CD3-1-Fc was evaluated in a system similar to that of Example 20, except that the target cells were hCCR8 / Fluc / Rat-1 cells of Example 5 or FLuc / ATN-1 cells of Example 7. The results are shown in Figure 26 (hCCR8 / Fluc / Rat-1 cells) and Figure 27 (FLuc / ATN-1 cells). The EC50 value against hCCR8 / FLuc / Rat-1 cells was 9.6 pM ± 24.6 pM (standard error), and the EC50 value against FLuc / ATN-1 was 13.4 nM ± 52.4 nM (standard error). These results demonstrate that the CCR8-CD3 bispecific antibody to which an Fc region has been added retains sufficient cytotoxic activity.

[0164] Example 23 Comparison of NF-AT promoter-inducing activity and cytotoxic activity with a CCR8-CD3 bispecific antibody based on Patent Document 20 (1) Preparation of a CCR8-CD3 bispecific antibody based on Patent Document 20 A CCR8-CD3 bispecific antibody (563-CCR8-CD3 (SEQ ID NO: 96)) having the amino acid sequence of SEQ ID NO: 96 was prepared based on the description of Patent Document 20. Note that, based on Example 4 of Patent Document 20, the anti-CCR8-scFv region in 563-CCR8-CD3 was constructed using the variable region sequence of Antibody 1, and the anti-CD3-scFv region was constructed using the variable region sequence of I2E antibody. The protein was prepared and purified in the same manner as in Example 2.

[0165] (2) Evaluation of NF-AT promoter induction activity We investigated whether binding of 563-CCR8-CD3 to human CCR8 and also to human CD3 activates the T cell receptor signal, which is a CD3 complex, and activates the NF-AT promoter downstream. We constructed a system that can detect not only trans-mediated activation between cells, but also cis-mediated activation of NFAT, in which CD3 is activated by the binding of CCR8 and CD3 present on the same cell membrane. We used the Jurkat cell line (NFAT-Jurkat), a human T cell line stably integrated into its genome with a reporter plasmid containing a luciferase gene as a reporter gene downstream of the NF-AT promoter (BPS Bioscience, NFAT Reporter (Luc)-Jurkat Cell line). The cells were transformed with the pQEF-hCCR8 plasmid (an expression vector in which the CMV promoter of pQCXIP was replaced with the EF promoter) that expresses human CCR8, and drug selection was performed with 1 μg / mL puromycin to establish cells stably expressing human CCR8 (hCCR8 / NFAT-Luc / Jurkat).

[0166] B6-CD3-1 or 563-CCR8-CD3 was added to these cells at final concentrations of 330 pM and 110 pM, and luciferase activity was compared and assessed 16 hours later (N=1). The luciferase activity without the addition of the bispecific antibody was set to 1, and the induction fold with the addition of the bispecific antibody was calculated.

[0167] The results are shown in Figure 28. For B6-CD3-1, the induction fold of luciferase activity was 10.7-fold and 27-fold at 330 pM and 110 pM, respectively. On the other hand, for 563-CCR8-CD3, the induction folds were 1.9-fold and 1.3-fold, respectively. From the above, it was demonstrated that 563-CCR8-CD3 constructed based on Patent Document 20 has a lower NFAT promoter induction ability compared to B6-CD3-1.

[0168] (3) Evaluation of Cytotoxic Activity The cytotoxic activity of B6-CD3-1 and 563-CCR8-CD3 was evaluated in the same system as in Example 20, except that the target cells were the hCCR8 / Fluc / Rat-1 cells of Example 5 (N=1). The bispecific antibody concentrations were 4.1 pM and 1.37 pM. The E / T cell ratio was 5:1.

[0169] The results are shown in Figure 29. B6-CD3-1 showed a killing activity of 60% or more at both concentrations, while the killing rate of 563-CCR8-CD3 was 14.7% at 4.1 pM and 1.33% at 1.37 pM.

[0170] Next, using FLuc / ATN-1 cells as target cells, cell killing activity was evaluated in the same system as in Example 20 (N=3). The bispecific antibody concentrations were varied from 32 pM to 0.125 pM in 3-fold dilutions. The E / T cell ratio was 5:1.

[0171] The results are shown in Figure 30. B6-CD3-1 exhibited cytotoxic activity with an EC50 value of 1.6 pM ± 0.25 pM, whereas 563-CCR8-CD3 showed no concentration-dependent killing. Student's t-test was performed at all measurement points, and the results showed that B6-CD3-1 exhibited significantly (P < 0.05) higher cytotoxic activity than 563-CCR8-CD3 at all measurement points with concentrations of 0.41 pM or higher. Furthermore, the cytotoxic activity of 563-CCR8-CD3 was 10% or less at all concentrations. From the above, it was demonstrated that 563-CCR8-CD3 constructed based on Patent Document 20 has lower cytotoxic activity than B6-CD3-1.

[0172] The bispecific antibodies of the present invention that recognize CCR8 as an antigen have cytotoxic activity against CCR8-expressing cells. Furthermore, the bispecific antibodies of the present invention that recognize CCR8 as an antigen exhibit antitumor effects. That is, the bispecific antibodies of the present invention that recognize CCR8 as an antigen are useful for the treatment and prevention of cancer.

Claims

1. A bispecific antibody comprising an anti-CCR8-scFv region comprising a light chain variable region and a heavy chain variable region of an anti-CCR8 antibody, and a region comprising one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell.

2. The anti-CCR8-scFv region comprises: 1) a light chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO:57, CDR2 having the amino acid sequence of SEQ ID NO:58, and CDR3 having the amino acid sequence of SEQ ID NO:59, and a heavy chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO:60, CDR2 having the amino acid sequence of SEQ ID NO:61, and CDR3 having the amino acid sequence of SEQ ID NO:62; 2) a light chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO:57, CDR2 having the amino acid sequence of SEQ ID NO:63, and CDR3 having the amino acid sequence of SEQ ID NO:59, and a heavy chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO:64, CDR2 having the amino acid sequence of SEQ ID NO:61, and CDR3 having the amino acid sequence of SEQ ID NO:65; 3) a light chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO:66, CDR2 having the amino acid sequence of SEQ ID NO:67, and CDR3 having the amino acid sequence of SEQ ID NO:68, and a CDR1 having the amino acid sequence of SEQ ID NO:69, 3) a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 72, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 67, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 73, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 74, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 75, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 76; or 5) a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 77, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 78, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 79, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 80, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 81, and a CDR3 consisting of the amino acid sequence of SEQ ID NO:

82.

3. The bispecific antibody according to claim 1, wherein the anti-CCR8-scFv region comprises: 1) a light chain variable region having the amino acid sequence of SEQ ID NO: 45 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 46; 2) a light chain variable region having the amino acid sequence of SEQ ID NO: 47 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 48; 3) a light chain variable region having the amino acid sequence of SEQ ID NO: 49 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50; 4) a light chain variable region having the amino acid sequence of SEQ ID NO: 51 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 52; 5) a light chain variable region having the amino acid sequence of SEQ ID NO: 53 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 54; or 6) a light chain variable region having the amino acid sequence of SEQ ID NO: 55 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:

56.

4. The bispecific antibody according to any one of claims 1 to 3, wherein in the anti-CCR8-scFv region, the light chain variable region and the heavy chain variable region are linked via a linker sequence of SEQ ID NO:

2.

5. A bispecific antibody according to any one of claims 1 to 4, which has a CD8A signal sequence region linked to its N-terminus.

6. The bispecific antibody according to claim 5, wherein the CD8A signal sequence region is present on the N-terminal side of the anti-CCR8-scFv region.

7. The bispecific antibody according to claim 5 or 6, wherein the CD8A signal sequence region has the amino acid sequence of SEQ ID NO:

1.

8. A bispecific antibody according to any one of claims 1 to 7, wherein the anti-CCR8-scFv region has an amino acid sequence of any one of SEQ ID NOs: 39 to 44.

9. A bispecific antibody according to any one of claims 1 to 8, wherein the effector cell is a T cell.

10. The bispecific antibody according to claim 9, wherein the T cell surface marker is CD3 and the bispecific antibody comprises an anti-CD3-scFv region comprising the light chain variable region and the heavy chain variable region of an antibody that recognizes CD3.

11. The anti-CD3-scFv region comprises: 1) a light chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO: 16, CDR2 having the amino acid sequence of SEQ ID NO: 17, and CDR3 having the amino acid sequence of SEQ ID NO: 18, and a heavy chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO: 19, CDR2 having the amino acid sequence of SEQ ID NO: 20, and CDR3 having the amino acid sequence of SEQ ID NO: 21; 2) a light chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO: 22, CDR2 having the amino acid sequence of SEQ ID NO: 23, and CDR3 having the amino acid sequence of SEQ ID NO: 24, and a heavy chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO: 25, CDR2 having the amino acid sequence of SEQ ID NO: 26, and CDR3 having the amino acid sequence of SEQ ID NO: 27; 3) a light chain variable region comprising CDR1 having the amino acid sequence of SEQ ID NO: 28, CDR2 having the amino acid sequence of SEQ ID NO: 29, and CDR3 having the amino acid sequence of SEQ ID NO: 30, and a CDR1 having the amino acid sequence of SEQ ID NO: 31, 11. The bispecific antibody according to claim 10, comprising: a heavy chain variable region comprising a CDR2 consisting of the amino acid sequence of SEQ ID NO: 32 and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 33; or 4) a light chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 87, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 88 and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 89, and a heavy chain variable region comprising a CDR1 consisting of the amino acid sequence of SEQ ID NO: 90, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 91 and a CDR3 consisting of the amino acid sequence of SEQ ID NO:

92.

12. The bispecific antibody according to claim 10, wherein the anti-CD3-scFv region comprises: 1) a light chain variable region having the amino acid sequence of SEQ ID NO: 10 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 11; 2) a light chain variable region having the amino acid sequence of SEQ ID NO: 12 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 13; 3) a light chain variable region having the amino acid sequence of SEQ ID NO: 14 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 15; or 4) a light chain variable region having the amino acid sequence of SEQ ID NO: 85 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:

86.

13. The bispecific antibody of claim 10, wherein the anti-CD3-scFv region has the amino acid sequence of SEQ ID NO: 7, 8, 9 or 84.

14. The bispecific antibody according to claim 9, wherein the T cell surface marker is CD3 and the bispecific antibody comprises an anti-CD3-VHH region comprising a heavy chain variable region of a VHH antibody that recognizes CD3.

15. The bispecific antibody of any one of claims 1 to 8, wherein the effector cell is a NK cell.

16. The bispecific antibody according to claim 15, wherein the surface marker of NK cells is CD16, and the bispecific antibody comprises an anti-CD16-scFv region comprising the light chain variable region and the heavy chain variable region of an antibody that recognizes CD16.

17. The bispecific antibody according to claim 15, wherein the surface marker for NK cells is CD16, and the bispecific antibody comprises an anti-CD16-VHH region comprising a heavy chain variable region of a VHH antibody that recognizes CD16.

18. A bispecific antibody according to claim 17, wherein the anti-CD16 VHH region comprises a heavy chain variable region comprising: CDR1 consisting of the amino acid sequence of SEQ ID NO: 35; CDR2 consisting of the amino acid sequence of SEQ ID NO: 36; and CDR3 consisting of the amino acid sequence of SEQ ID NO:

37.

19. The bispecific antibody according to claim 17, wherein the anti-CD16 VHH domain has the amino acid sequence of SEQ ID NO:

34.

20. A bispecific antibody according to any one of claims 1 to 19, in which an anti-CCR8-scFv region comprising the light chain variable region and heavy chain variable region of an anti-CCR8 antibody and a region comprising one or more light chain or heavy chain variable regions of an antibody that recognizes a surface marker of an effector cell are linked via an scFv linker sequence of any one of SEQ ID NOs: 3 to 6.

21. A bispecific antibody according to any one of claims 1 to 20, which has a histidine tag having the amino acid sequence of SEQ ID NO:38 added to its C-terminus.

22. A bispecific antibody according to any one of claims 1 to 21, having an Fc region.

23. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 1 to 22.

24. The pharmaceutical composition according to claim 23, for use in treating cancer.

25. The pharmaceutical composition according to claim 24, which has the effect of eliminating tumor-infiltrating Treg cells that express CCR8.

26. The pharmaceutical composition according to claim 24, which is used to treat a cancer in which CCR8 is not expressed in tumor cells.

27. The pharmaceutical composition according to claim 24, which is used to treat a cancer in which CCR8 is expressed in tumor cells.

28. A polynucleotide encoding the amino acid sequence of a bispecific antibody according to any one of claims 1 to 22.

29. An expression vector comprising the polynucleotide of claim 28.

Citation Information

Patent Citations

  • Depleting tumor-specific tregs

    US10087259B1

  • CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

    WO1999054440A1

  • Function of chemokine receptor CCR8 in melanoma metastasis

    WO2013131010A2

  • Heterodimeric antibodies that bind CD3 and tumor antigens

    WO2016182751A1

  • PSMA and CD3 bispecific t cell engaging antibody constructs

    WO2017134158A1